1

# **Medical Cannabis Modifications**

# 2025 GENERAL SESSION

# STATE OF UTAH

# **Chief Sponsor: Raymond P. Ward**

Senate Sponsor: Luz Escamilla

]	LONG TITLE
	General Description:
	This bill amends provisions related to medical cannabis.
	Highlighted Provisions:
	This bill:
	<ul> <li>repeals provisions related to qualified medical providers and limited medical providers in</li> </ul>
	the medical cannabis program;
	<ul> <li>allows certain health care providers to recommend medical cannabis without first</li> </ul>
	registering with the Department of Health and Human Services;
	<ul> <li>repeals continuing education requirements related to medical cannabis;</li> </ul>
	<ul> <li>moves enforcement of advertising and payment requirements related to medical cannabis</li> </ul>
	from the Department of Health and Human Services to the Division of Professional
	Licensing; and
	<ul> <li>makes technical and conforming changes.</li> </ul>
	Money Appropriated in this Bill:
	None
	Other Special Clauses:
	None
	Utah Code Sections Affected:
	AMENDS:
	4-41a-102, as last amended by Laws of Utah 2024, Chapters 217, 238 and 240
	4-41a-301, as last amended by Laws of Utah 2024, Chapter 217
	4-41a-602, as last amended by Laws of Utah 2024, Chapter 217
	4-41a-1101, as last amended by Laws of Utah 2024, Chapter 217
	26B-1-435, as last amended by Laws of Utah 2024, Chapters 238, 240
	26B-4-201, as last amended by Laws of Utah 2024, Chapters 217, 240
	26B-4-202, as last amended by Laws of Utah 2024, Chapters 217, 240
	26B-4-203, as last amended by Laws of Utah 2023, Chapter 317 and renumbered and

31	amended by Laws of Utah 2023, Chapter 307
32	26B-4-204, as last amended by Laws of Utah 2024, Chapter 217
33	26B-4-205, as renumbered and amended by Laws of Utah 2023, Chapter 307
34	26B-4-213, as last amended by Laws of Utah 2024, Chapters 217, 240
35	26B-4-214, as last amended by Laws of Utah 2024, Chapter 240
36	26B-4-231, as last amended by Laws of Utah 2024, Chapter 238
37	26B-4-245, as last amended by Laws of Utah 2024, Chapters 217, 240
38	58-5a-102, as last amended by Laws of Utah 2024, Chapter 458
39	58-31b-305, as last amended by Laws of Utah 2023, Chapter 329
40	58-31b-502, as last amended by Laws of Utah 2024, Chapter 237
41	58-67-304, as last amended by Laws of Utah 2023, Chapters 301, 329
42	58-67-502, as last amended by Laws of Utah 2024, Chapter 237
43	58-68-304, as last amended by Laws of Utah 2023, Chapters 301, 329
44	58-68-502, as last amended by Laws of Utah 2024, Chapter 237
45	58-70a-303, as last amended by Laws of Utah 2023, Chapter 329
46	58-70a-503, as last amended by Laws of Utah 2024, Chapter 237
47	80-4-109, as last amended by Laws of Utah 2023, Chapters 273, 317 and 330 and last
48	amended by Coordination Clause, Laws of Utah 2023, Chapter 330
49	ENACTS:
50	58-1-513, Utah Code Annotated 1953
51	
52	Be it enacted by the Legislature of the state of Utah:
53	Section 1. Section 4-41a-102 is amended to read:
54	4-41a-102 . Definitions.
55	As used in this chapter:
56	(1) "Adulterant" means any poisonous or deleterious substance in a quantity that may be
57	injurious to health, including:
58	(a) pesticides;
59	(b) heavy metals;
60	(c) solvents;
61	(d) microbial life;
62	(e) artificially derived cannabinoid;
63	(f) toxins; or
64	(g) foreign matter.

65	(2) "Advertise" or "advertising" means information provided by a person in any medium:
66	(a) to the public; and
67	(b) that is not age restricted to an individual who is at least 21 years old.
68	(3) "Advisory board" means the Medical Cannabis Policy Advisory Board created in
69	Section 26B-1-435.
70	(4)(a) "Anticompetitive business practice" means any practice that reduces the amount
71	of competition in the medical cannabis market that would be considered an attempt to
72	monopolize, as defined in Section 76-10-3103.
73	(b) "Anticompetitive business practice" may include:
74	(i) agreements that may be considered unreasonable when competitors interact to the
75	extent that they are:
76	(A) no longer acting independently; or
77	(B) when collaborating are able to wield market power together;
78	(ii) monopolizing or attempting to monopolize trade by:
79	(A) acting to maintain or acquire a dominant position in the market; or
80	(B) preventing new entry into the market; or
81	(iii) other conduct outlined in rule.
82	(5)(a) "Artificially derived cannabinoid" means a chemical substance that is created by a
83	chemical reaction that changes the molecular structure of any chemical substance
84	derived from the cannabis plant.
85	(b) "Artificially derived cannabinoid" does not include:
86	(i) a naturally occurring chemical substance that is separated from the cannabis plant
87	by a chemical or mechanical extraction process; or
88	(ii) a cannabinoid that is produced by decarboxylation from a naturally occurring
89	cannabinoid acid without the use of a chemical catalyst.
90	(6) "Cannabis Research Review Board" means the Cannabis Research Review Board
91	created in Section 26B-1-420.
92	(7) "Cannabis" means the same as that term is defined in Section 26B-4-201.
93	(8) "Cannabis concentrate" means:
94	(a) the product of any chemical or physical process applied to naturally occurring
95	biomass that concentrates or isolates the cannabinoids contained in the biomass; and
96	(b) any amount of a natural cannabinoid or artificially derived cannabinoid in an
97	artificially derived cannabinoid's purified state.
98	(9) "Cannabis cultivation byproduct" means any portion of a cannabis plant that is not

99	intended to be sold as a cannabis plant product.
100	(10) "Cannabis cultivation facility" means a person that:
101	(a) possesses cannabis;
102	(b) grows or intends to grow cannabis; and
103	(c) sells or intends to sell cannabis to a cannabis cultivation facility, a cannabis
104	processing facility, or a medical cannabis research licensee.
105	(11) "Cannabis cultivation facility agent" means an individual who
106	holds a valid cannabis production establishment agent registration card with a cannabis
107	cultivation facility designation.
108	(12) "Cannabis derivative product" means a product made using cannabis concentrate.
109	(13) "Cannabis plant product" means any portion of a cannabis plant intended to be sold in
110	a form that is recognizable as a portion of a cannabis plant.
111	(14) "Cannabis processing facility" means a person that:
112	(a) acquires or intends to acquire cannabis from a cannabis production establishment;
113	(b) possesses cannabis with the intent to manufacture a cannabis product;
114	(c) manufactures or intends to manufacture a cannabis product from unprocessed
115	cannabis or a cannabis extract; and
116	(d) sells or intends to sell a cannabis product to a medical cannabis pharmacy or a
117	medical cannabis research licensee.
118	(15) "Cannabis processing facility agent" means an individual who
119	holds a valid cannabis production establishment agent registration card with a cannabis
120	processing facility designation.
121	(16) "Cannabis product" means the same as that term is defined in Section 26B-4-201.
122	(17) "Cannabis production establishment" means a cannabis cultivation facility, a cannabis
123	processing facility, or an independent cannabis testing laboratory.
124	(18) "Cannabis production establishment agent" means a cannabis cultivation facility agent,
125	a cannabis processing facility agent, or an independent cannabis testing laboratory agent.
126	(19) "Cannabis production establishment agent registration card" means a registration card
127	that the department issues that:
128	(a) authorizes an individual to act as a cannabis production establishment agent; and
129	(b) designates the type of cannabis production establishment for which an individual is
130	authorized to act as an agent.
131	(20) "Closed-door medical cannabis pharmacy" means a facility operated by a home
132	delivery medical cannabis pharmacy for delivering cannabis or a medical cannabis

133	product.
134	(21) "Community location" means a public or private elementary or secondary school, a
135	church, a public library, a public playground, or a public park.
136	(22) "Cultivation space" means, quantified in square feet, the horizontal area in which a
137	cannabis cultivation facility cultivates cannabis, including each level of horizontal area
138	if the cannabis cultivation facility hangs, suspends, stacks, or otherwise positions plants
139	above other plants in multiple levels.
140	(23) "Delivery address" means:
141	(a) for a medical cannabis cardholder who is not a facility:
142	(i) the medical cannabis cardholder's home address; or
143	(ii) an address designated by the medical cannabis cardholder that:
144	(A) is the medical cannabis cardholder's workplace; and
145	(B) is not a community location; or
146	(b) for a medical cannabis cardholder that is a facility, the facility's address.
147	(24) "Department" means the Department of Agriculture and Food.
148	(25) "Family member" means a parent, step-parent, spouse, child, sibling, step-sibling,
149	uncle, aunt, nephew, niece, first cousin, mother-in-law, father-in-law, brother-in-law,
150	sister-in-law, son-in-law, daughter-in-law, grandparent, or grandchild.
151	(26) "Government issued photo identification" means the same as that term is defined in
152	Section 26B-4-201, including expired identification in accordance with Section
153	26B-4-244.
154	(27) "Home delivery medical cannabis pharmacy" means a medical cannabis pharmacy that
155	the department authorizes, as part of the pharmacy's license, to deliver medical cannabis
156	shipments to a delivery address to fulfill electronic orders that the state central patient
157	portal facilitates.
158	(28)(a) "Independent cannabis testing laboratory" means a person that:
159	(i) conducts a chemical or other analysis of cannabis or a cannabis product; or
160	(ii) acquires, possesses, and transports cannabis or a cannabis product with the intent
161	to conduct a chemical or other analysis of the cannabis or cannabis product.
162	(b) "Independent cannabis testing laboratory" includes a laboratory that the department
163	or a research university operates in accordance with Subsection 4-41a-201(14).
164	(29) "Independent cannabis testing laboratory agent" means an individual who
165	holds a valid cannabis production establishment agent registration card with an
166	independent cannabis testing laboratory designation.

167	(30) "Inventory control system" means a system described in Section 4-41a-103.
168	(31) "Licensing board" or "board" means the Cannabis Production Establishment and
169	Pharmacy Licensing Advisory Board created in Section 4-41a-201.1.
170	(32) "Medical cannabis" means the same as that term is defined in Section 26B-4-201.
171	(33) "Medical cannabis card" means the same as that term is defined in Section 26B-4-201.
172	(34) "Medical cannabis courier" means a courier that:
173	(a) the department licenses in accordance with Section 4-41a-1201; and
174	(b) contracts with a home delivery medical cannabis pharmacy to deliver medical
175	cannabis shipments to fulfill electronic orders that the state central patient portal
176	facilitates.
177	(35) "Medical cannabis courier agent" means an individual who:
178	(a) is an employee of a medical cannabis courier; and
179	(b) who holds a valid medical cannabis courier agent registration card.
180	(36) "Medical cannabis pharmacy" means the same as that term is defined in Section
181	26B-4-201.
182	(37) "Medical cannabis pharmacy agent" means the same as that term is defined in Section
183	26B-4-201.
184	(38) "Medical cannabis research license" means a license that the department issues to a
185	research university for the purpose of obtaining and possessing medical cannabis for
186	academic research.
187	(39) "Medical cannabis research licensee" means a research university that the department
188	licenses to obtain and possess medical cannabis for academic research, in accordance
189	with Section 4-41a-901.
190	(40) "Medical cannabis shipment" means a shipment of medical cannabis that a home
191	delivery medical cannabis pharmacy or a medical cannabis courier delivers to a delivery
192	address to fulfill an electronic medical cannabis order that the state central patient portal
193	facilitates.
194	(41) "Medical cannabis treatment" means the same as that term is defined in Section
195	26B-4-201.
196	(42) "Medicinal dosage form" means the same as that term is defined in Section 26B-4-201.
197	(43) "Pharmacy ownership limit" means an amount equal to 30% of the total number of
198	medical cannabis pharmacy licenses issued by the department rounded down to the
199	nearest whole number.
200	(44) "Pharmacy medical provider" means the same as that term is defined in Section

- 6 -

201	26B-4-201.
202	[(45) "Qualified medical provider" means the same as that term is defined in Section
203	<del>26B-4-201.</del> ]
204	[(46)] (45) "Qualified Production Enterprise Fund" means the fund created in Section
205	4-41a-104.
206	[(47)] (46) "Recommending medical provider" means the same as that term is defined in
207	Section 26B-4-201.
208	[(48)] (47) "Research university" means the same as that term is defined in Section
209	53B-7-702 and a private, nonprofit college or university in the state that:
210	(a) is accredited by the Northwest Commission on Colleges and Universities;
211	(b) grants doctoral degrees; and
212	(c) has a laboratory containing or a program researching a schedule I controlled
213	substance described in Section 58-37-4.
214	[(49)] (48) "State electronic verification system" means the system described in Section
215	26B-4-202.
216	[(50)] (49) "Targeted marketing" means the promotion of a cannabis product, medical
217	cannabis brand, or a medical cannabis device using any of the following methods:
218	(a) electronic communication to an individual who is at least 21 years old and has
219	requested to receive promotional information;
220	(b) an in-person marketing event that is:
221	(i) held inside a medical cannabis pharmacy; and
222	(ii) in an area where only a medical cannabis cardholder may access the event;
223	(c) other marketing material that is physically available or digitally displayed in a
224	medical cannabis pharmacy; or
225	(d) a leaflet a medical cannabis pharmacy places in the opaque package or box that is
226	provided to an individual when obtaining medical cannabis:
227	(i) in the medical cannabis pharmacy;
228	(ii) at the medical cannabis pharmacy's drive-through pick up window; or
229	(iii) in a medical cannabis shipment.
230	[(51)] (50) "Tetrahydrocannabinol" or "THC" means the same as that term is defined in
231	Section 4-41-102.
232	[(52)] (51) "THC analog" means the same as that term is defined in Section 4-41-102.
233	[(53)] (52) "Total composite tetrahydrocannabinol" means all detectable forms of
234	tetrahydrocannabinol.

235	[(54)] (53) "Total tetrahydrocannabinol" or "total THC" means the same as that term is
236	defined in Section 4-41-102.
237	Section 2. Section <b>4-41a-301</b> is amended to read:
238	4-41a-301 . Cannabis production establishment agent Registration.
239	(1) An individual may not act as a cannabis production establishment agent unless the
240	department registers the individual as a cannabis production establishment agent,
241	regardless of whether the individual is a seasonal, temporary, or permanent employee.
242	(2) The following individuals, regardless of the individual's status as a [qualified medical
243	provider] recommending medical provider, may not serve as a cannabis production
244	establishment agent, have a financial or voting interest of 2% or greater in a cannabis
245	production establishment, or have the power to direct or cause the management or
246	control of a cannabis production establishment:
247	(a) a pharmacist licensed under Title 58, Chapter 17b, Pharmacy Practice Act;
248	(b) an advanced practice registered nurse licensed under Title 58, Chapter 31b, Nurse
249	Practice Act;
250	(c) a physician licensed under Title 58, Chapter 67, Utah Medical Practice Act, or Title
251	58, Chapter 68, Utah Osteopathic Medical Practice Act; or
252	(d) a physician assistant licensed under Title 58, Chapter 70a, Utah Physician Assistant
253	Act.
254	(3) An independent cannabis testing laboratory agent may not act as an agent for a medical
255	cannabis pharmacy, a medical cannabis courier, a cannabis processing facility, or a
256	cannabis cultivation facility.
257	(4)(a) The department shall, within 15 business days after the day on which the
258	department receives a complete application from a prospective cannabis production
259	establishment agent, register and issue a cannabis production establishment agent
260	registration card to the prospective agent if the prospective agent:
261	(i) provides to the department:
262	(A) the prospective agent's name and address;
263	(B) which cannabis production establishment agent designations the applicant
264	desires; and
265	(C) the submission required under Subsection (4)(b); and
266	(ii) pays a fee to the department in an amount that, subject to Subsection 4-41a-104(5),
267	the department sets in accordance with Section 63J-1-504.
268	(b) Each prospective agent described in Subsection (4)(a) shall:

<ul> <li>(A) a fingerprint card in a form acceptable to the Department of Public Safety; and</li> <li>(B) a signed waiver in accordance with Subsection 53-10-108(4) acknowledging</li> <li>the registration of the prospective agent's fingerprints in the Federal Bureau of</li> <li>Investigation Next Generation Identification System's Rap Back Service; and</li> <li>(ii) consent to a fingerprint background check by:</li> <li>(A) the Bureau of Criminal Identification; and</li> <li>(B) the Federal Bureau of Investigation.</li> <li>(C) The Bureau of Criminal Identification shall:</li> <li>(i) check the fingerprints the prospective agent submits under Subsection (4)(b)</li> <li>against the applicable state, regional, and national criminal records databases,</li> <li>including the Federal Bureau of Investigation Next Generation Identification</li> <li>System;</li> <li>(ii) report the results of the background check to the department;</li> <li>(iii) maintain a separate file of fingerprints that prospective agents submit under</li> <li>Subsection (4)(b) for search by future submissions to the local and regional</li> <li>criminal records databases, including latent prints;</li> <li>(iv) request that the fingerprints be retained in the Federal Bureau of Investigation</li> <li>Next Generation Identification System's Rap Back Service for search by future</li> <li>submissions to national criminal records databases, including the Next Generation</li> <li>(v) establish a privacy risk mitigation strategy to ensure that the department only</li> <li>receives notifications for an individual with whom the department maintains an</li> </ul>
272the registration of the prospective agent's fingerprints in the Federal Bureau of273Investigation Next Generation Identification System's Rap Back Service; and274(ii) consent to a fingerprint background check by:275(A) the Bureau of Criminal Identification; and276(B) the Federal Bureau of Investigation.277(c) The Bureau of Criminal Identification shall:278(i) check the fingerprints the prospective agent submits under Subsection (4)(b)279against the applicable state, regional, and national criminal records databases,280including the Federal Bureau of Investigation Next Generation Identification281System;282(ii) report the results of the background check to the department;283(iii) maintain a separate file of fingerprints that prospective agents submit under284Subsection (4)(b) for search by future submissions to the local and regional285criminal records databases, including latent prints;286(iv) request that the fingerprints be retained in the Federal Bureau of Investigation287Next Generation Identification System's Rap Back Service for search by future288submissions to national criminal records databases, including the Next Generation289Identification System and latent prints; and290(v) establish a privacy risk mitigation strategy to ensure that the department only291receives notifications for an individual with whom the department maintains an
273Investigation Next Generation Identification System's Rap Back Service; and274(ii) consent to a fingerprint background check by:275(A) the Bureau of Criminal Identification; and276(B) the Federal Bureau of Investigation.277(c) The Bureau of Criminal Identification shall:278(i) check the fingerprints the prospective agent submits under Subsection (4)(b)279against the applicable state, regional, and national criminal records databases,280including the Federal Bureau of Investigation Next Generation Identification281System;282(ii) report the results of the background check to the department;283(iii) maintain a separate file of fingerprints that prospective agents submit under284Subsection (4)(b) for search by future submissions to the local and regional285criminal records databases, including latent prints;286(iv) request that the fingerprints be retained in the Federal Bureau of Investigation287Next Generation Identification System's Rap Back Service for search by future288submissions to national criminal records databases, including the Next Generation289Identification System and latent prints; and290(v) establish a privacy risk mitigation strategy to ensure that the department only291receives notifications for an individual with whom the department maintains an
<ul> <li>(ii) consent to a fingerprint background check by:</li> <li>(A) the Bureau of Criminal Identification; and</li> <li>(B) the Federal Bureau of Investigation.</li> <li>(c) The Bureau of Criminal Identification shall:</li> <li>(i) check the fingerprints the prospective agent submits under Subsection (4)(b)</li> <li>against the applicable state, regional, and national criminal records databases,</li> <li>including the Federal Bureau of Investigation Next Generation Identification</li> <li>System;</li> <li>(ii) report the results of the background check to the department;</li> <li>(iii) maintain a separate file of fingerprints that prospective agents submit under</li> <li>Subsection (4)(b) for search by future submissions to the local and regional</li> <li>criminal records databases, including latent prints;</li> <li>(iv) request that the fingerprints be retained in the Federal Bureau of Investigation</li> <li>Next Generation Identification System's Rap Back Service for search by future</li> <li>submissions to national criminal records databases, including the Next Generation</li> <li>(v) establish a privacy risk mitigation strategy to ensure that the department only</li> <li>receives notifications for an individual with whom the department maintains an</li> </ul>
<ul> <li>(A) the Bureau of Criminal Identification; and</li> <li>(B) the Federal Bureau of Investigation.</li> <li>(c) The Bureau of Criminal Identification shall:</li> <li>(i) check the fingerprints the prospective agent submits under Subsection (4)(b)</li> <li>against the applicable state, regional, and national criminal records databases,</li> <li>including the Federal Bureau of Investigation Next Generation Identification</li> <li>System;</li> <li>(ii) report the results of the background check to the department;</li> <li>(iii) maintain a separate file of fingerprints that prospective agents submit under</li> <li>Subsection (4)(b) for search by future submissions to the local and regional</li> <li>criminal records databases, including latent prints;</li> <li>(iv) request that the fingerprints be retained in the Federal Bureau of Investigation</li> <li>Next Generation Identification System's Rap Back Service for search by future</li> <li>submissions to national criminal records databases, including the Next Generation</li> <li>Identification System and latent prints; and</li> <li>(v) establish a privacy risk mitigation strategy to ensure that the department only</li> <li>receives notifications for an individual with whom the department maintains an</li> </ul>
<ul> <li>(B) the Federal Bureau of Investigation.</li> <li>(c) The Bureau of Criminal Identification shall:</li> <li>(i) check the fingerprints the prospective agent submits under Subsection (4)(b)</li> <li>against the applicable state, regional, and national criminal records databases,</li> <li>including the Federal Bureau of Investigation Next Generation Identification</li> <li>System;</li> <li>(ii) report the results of the background check to the department;</li> <li>(iii) maintain a separate file of fingerprints that prospective agents submit under</li> <li>Subsection (4)(b) for search by future submissions to the local and regional</li> <li>criminal records databases, including latent prints;</li> <li>(iv) request that the fingerprints be retained in the Federal Bureau of Investigation</li> <li>Next Generation Identification System's Rap Back Service for search by future</li> <li>submissions to national criminal records databases, including the Next Generation</li> <li>Identification System and latent prints; and</li> <li>(v) establish a privacy risk mitigation strategy to ensure that the department only</li> <li>receives notifications for an individual with whom the department maintains an</li> </ul>
<ul> <li>(c) The Bureau of Criminal Identification shall:</li> <li>(i) check the fingerprints the prospective agent submits under Subsection (4)(b)</li> <li>against the applicable state, regional, and national criminal records databases,</li> <li>including the Federal Bureau of Investigation Next Generation Identification</li> <li>System;</li> <li>(ii) report the results of the background check to the department;</li> <li>(iii) maintain a separate file of fingerprints that prospective agents submit under</li> <li>Subsection (4)(b) for search by future submissions to the local and regional</li> <li>criminal records databases, including latent prints;</li> <li>(iv) request that the fingerprints be retained in the Federal Bureau of Investigation</li> <li>Next Generation Identification System's Rap Back Service for search by future</li> <li>submissions to national criminal records databases, including the Next Generation</li> <li>Identification System and latent prints; and</li> <li>(v) establish a privacy risk mitigation strategy to ensure that the department only</li> <li>receives notifications for an individual with whom the department maintains an</li> </ul>
<ul> <li>(i) check the fingerprints the prospective agent submits under Subsection (4)(b)</li> <li>against the applicable state, regional, and national criminal records databases,</li> <li>including the Federal Bureau of Investigation Next Generation Identification</li> <li>System;</li> <li>(ii) report the results of the background check to the department;</li> <li>(iii) maintain a separate file of fingerprints that prospective agents submit under</li> <li>Subsection (4)(b) for search by future submissions to the local and regional</li> <li>criminal records databases, including latent prints;</li> <li>(iv) request that the fingerprints be retained in the Federal Bureau of Investigation</li> <li>Next Generation Identification System's Rap Back Service for search by future</li> <li>submissions to national criminal records databases, including the Next Generation</li> <li>Identification System and latent prints; and</li> <li>(v) establish a privacy risk mitigation strategy to ensure that the department only</li> <li>receives notifications for an individual with whom the department maintains an</li> </ul>
279against the applicable state, regional, and national criminal records databases,280including the Federal Bureau of Investigation Next Generation Identification281System;282(ii) report the results of the background check to the department;283(iii) maintain a separate file of fingerprints that prospective agents submit under284Subsection (4)(b) for search by future submissions to the local and regional285criminal records databases, including latent prints;286(iv) request that the fingerprints be retained in the Federal Bureau of Investigation287Next Generation Identification System's Rap Back Service for search by future288submissions to national criminal records databases, including the Next Generation289Identification System and latent prints; and290(v) establish a privacy risk mitigation strategy to ensure that the department only receives notifications for an individual with whom the department maintains an
<ul> <li>including the Federal Bureau of Investigation Next Generation Identification</li> <li>System;</li> <li>(ii) report the results of the background check to the department;</li> <li>(iii) maintain a separate file of fingerprints that prospective agents submit under</li> <li>Subsection (4)(b) for search by future submissions to the local and regional</li> <li>criminal records databases, including latent prints;</li> <li>(iv) request that the fingerprints be retained in the Federal Bureau of Investigation</li> <li>Next Generation Identification System's Rap Back Service for search by future</li> <li>submissions to national criminal records databases, including the Next Generation</li> <li>Identification System and latent prints; and</li> <li>(v) establish a privacy risk mitigation strategy to ensure that the department only</li> <li>receives notifications for an individual with whom the department maintains an</li> </ul>
281System;282(ii) report the results of the background check to the department;283(iii) maintain a separate file of fingerprints that prospective agents submit under284Subsection (4)(b) for search by future submissions to the local and regional285criminal records databases, including latent prints;286(iv) request that the fingerprints be retained in the Federal Bureau of Investigation287Next Generation Identification System's Rap Back Service for search by future288submissions to national criminal records databases, including the Next Generation289Identification System and latent prints; and290(v) establish a privacy risk mitigation strategy to ensure that the department only receives notifications for an individual with whom the department maintains an
<ul> <li>(ii) report the results of the background check to the department;</li> <li>(iii) maintain a separate file of fingerprints that prospective agents submit under</li> <li>Subsection (4)(b) for search by future submissions to the local and regional</li> <li>criminal records databases, including latent prints;</li> <li>(iv) request that the fingerprints be retained in the Federal Bureau of Investigation</li> <li>Next Generation Identification System's Rap Back Service for search by future</li> <li>submissions to national criminal records databases, including the Next Generation</li> <li>Identification System and latent prints; and</li> <li>(v) establish a privacy risk mitigation strategy to ensure that the department only</li> <li>receives notifications for an individual with whom the department maintains an</li> </ul>
<ul> <li>(iii) maintain a separate file of fingerprints that prospective agents submit under</li> <li>Subsection (4)(b) for search by future submissions to the local and regional</li> <li>criminal records databases, including latent prints;</li> <li>(iv) request that the fingerprints be retained in the Federal Bureau of Investigation</li> <li>Next Generation Identification System's Rap Back Service for search by future</li> <li>submissions to national criminal records databases, including the Next Generation</li> <li>Identification System and latent prints; and</li> <li>(v) establish a privacy risk mitigation strategy to ensure that the department only</li> <li>receives notifications for an individual with whom the department maintains an</li> </ul>
<ul> <li>Subsection (4)(b) for search by future submissions to the local and regional</li> <li>criminal records databases, including latent prints;</li> <li>(iv) request that the fingerprints be retained in the Federal Bureau of Investigation</li> <li>Next Generation Identification System's Rap Back Service for search by future</li> <li>submissions to national criminal records databases, including the Next Generation</li> <li>Identification System and latent prints; and</li> <li>(v) establish a privacy risk mitigation strategy to ensure that the department only</li> <li>receives notifications for an individual with whom the department maintains an</li> </ul>
<ul> <li>criminal records databases, including latent prints;</li> <li>(iv) request that the fingerprints be retained in the Federal Bureau of Investigation</li> <li>Next Generation Identification System's Rap Back Service for search by future</li> <li>submissions to national criminal records databases, including the Next Generation</li> <li>Identification System and latent prints; and</li> <li>(v) establish a privacy risk mitigation strategy to ensure that the department only</li> <li>receives notifications for an individual with whom the department maintains an</li> </ul>
<ul> <li>(iv) request that the fingerprints be retained in the Federal Bureau of Investigation</li> <li>Next Generation Identification System's Rap Back Service for search by future</li> <li>submissions to national criminal records databases, including the Next Generation</li> <li>Identification System and latent prints; and</li> <li>(v) establish a privacy risk mitigation strategy to ensure that the department only</li> <li>receives notifications for an individual with whom the department maintains an</li> </ul>
<ul> <li>287 Next Generation Identification System's Rap Back Service for search by future</li> <li>288 submissions to national criminal records databases, including the Next Generation</li> <li>289 Identification System and latent prints; and</li> <li>290 (v) establish a privacy risk mitigation strategy to ensure that the department only</li> <li>291 receives notifications for an individual with whom the department maintains an</li> </ul>
<ul> <li>submissions to national criminal records databases, including the Next Generation</li> <li>Identification System and latent prints; and</li> <li>(v) establish a privacy risk mitigation strategy to ensure that the department only</li> <li>receives notifications for an individual with whom the department maintains an</li> </ul>
<ul> <li>Identification System and latent prints; and</li> <li>(v) establish a privacy risk mitigation strategy to ensure that the department only</li> <li>receives notifications for an individual with whom the department maintains an</li> </ul>
<ul> <li>(v) establish a privacy risk mitigation strategy to ensure that the department only</li> <li>receives notifications for an individual with whom the department maintains an</li> </ul>
291 receives notifications for an individual with whom the department maintains an
authorizing relationship.
293 (d) The department shall:
(i) assess an individual who submits fingerprints under Subsection (4)(b) a fee in an
amount that the department sets in accordance with Section 63J-1-504 for the
296 services that the Bureau of Criminal Identification or another authorized agency
297 provides under this section; and
(ii) remit the fee described in Subsection (4)(d)(i) to the Bureau of Criminal
299Identification.
300 (5)(a) The department shall designate, on an individual's cannabis production establishment
301 agent registration card
302 the type of cannabis production establishment for which the individual is authorized to

303	act as an agent.
304	(b) When issuing a card under Subsection (5)(a) the department:
305	(i) may issue a cannabis production establishment agent registration card that
306	contains both a cannabis processing facility designation and a cannabis cultivator
307	facility designation; and
308	(ii) if the cannabis production establishment agent registration card will contain an
309	independent cannabis testing laboratory designation, may not include any other
310	designations.
311	(6) A cannabis production establishment agent shall comply with:
312	(a) a certification standard that the department develops; or
313	(b) a certification standard that the department has reviewed and approved.
314	(7)(a) The department shall ensure that the certification standard described in Subsection
315	(6) includes training:
316	(i) in Utah medical cannabis law;
317	(ii) for a cannabis cultivation facility agent, in cannabis cultivation best practices;
318	(iii) for a cannabis processing facility agent, in cannabis processing, manufacturing
319	safety procedures for items for human consumption, and sanitation best practices;
320	and
321	(iv) for an independent cannabis testing laboratory agent, in cannabis testing best
322	practices.
323	(b) The department shall review the training described in Subsection (7)(a) annually or
324	as often as necessary to ensure compliance with this section.
325	(8) For an individual who holds or applies for a cannabis production establishment agent
326	registration card:
327	(a) the department may revoke or refuse to issue the card if the individual violates the
328	requirements of this chapter; and
329	(b) the department shall revoke or refuse to issue the card if the individual is convicted
330	under state or federal law of:
331	(i) a felony in the preceding 10 years; or
332	(ii) after December 3, 2018, a misdemeanor for drug distribution.
333	(9)(a) A cannabis production establishment agent registration card expires two years
334	after the day on which the department issues the card.
335	(b) A cannabis production establishment agent may renew the agent's registration card if
336	the agent:

337	(i) is eligible for a cannabis production establishment registration card under this
338	section;
339	(ii) certifies to the department in a renewal application that the information in
340	Subsection (4)(a) is accurate or updates the information; and
341	(iii) pays to the department a renewal fee in an amount that:
342	(A) subject to Subsection 4-41a-104(5), the department sets in accordance with
343	Section 63J-1-504; and
344	(B) may not exceed the cost of the relatively lower administrative burden of
345	renewal in comparison to the original application process.
346	(10) A cannabis production establishment shall:
347	(a) maintain a list of each employee that holds a cannabis production establishment
348	agent registration card; and
349	(b) provide the list to the department upon request.
350	Section 3. Section 4-41a-602 is amended to read:
351	4-41a-602 . Cannabis product Labeling and child-resistant packaging.
352	(1) For any cannabis product that a cannabis processing facility processes or produces and
353	for any raw cannabis that the facility packages, the facility shall:
354	(a) label the cannabis or cannabis product with a label that:
355	(i) clearly and unambiguously states that the cannabis product or package contains
356	cannabis;
357	(ii) clearly displays the amount of total composite tetrahydrocannabinol, cannabidiol,
358	and any known cannabinoid that is greater than 1% of the total cannabinoids
359	contained in the cannabis or cannabis product as determined under Subsection
360	4-41a-701(4);
361	(iii) has a unique identification number that:
362	(A) is connected to the inventory control system; and
363	(B) identifies the unique cannabis product manufacturing process the cannabis
364	processing facility used to manufacture the cannabis product;
365	(iv) identifies the cannabinoid extraction process that the cannabis processing facility
366	used to create the cannabis product;
367	(v) does not display an image, word, or phrase that the facility knows or should know
368	appeals to children; and
369	(vi) discloses each active or potentially active ingredient, in order of prominence, and
370	possible allergen; and

371	(b) package the raw cannabis or cannabis product in a medicinal dosage form in a
372	container that:
373	(i) is tamper evident and tamper resistant;
374	(ii) does not appeal to children;
375	(iii) does not mimic a candy container;
376	(iv) complies with child-resistant effectiveness standards that the United States
377	Consumer Product Safety Commission establishes;
378	(v) includes a warning label that states:
379	[(A) for a container labeled before July 1, 2021, "WARNING: Cannabis has
380	intoxicating effects and may be addictive. Do not operate a vehicle or
381	machinery under its influence. KEEP OUT OF REACH OF CHILDREN. This
382	product is for medical use only. Use only as directed by a qualified medical
383	provider.";]
384	[(B)] (A) for a container labeled on or after July 1, 2021, "WARNING: Cannabis
385	has intoxicating effects and may be addictive. Do not operate a vehicle or
386	machinery under its influence. KEEP OUT OF REACH OF CHILDREN. This
387	product is for medical use only. Use only as directed by a recommending
388	medical provider."; or
389	[(C)] (B) for a container labeled on or after January 1, 2024, "WARNING:
390	Cannabis has intoxicating effects, may be addictive, and may increase risk of
391	mental illness. Do not operate a vehicle or machinery under its influence.
392	KEEP OUT OF REACH OF CHILDREN. This product is for medical use
393	only. Use only as directed by a recommending medical provider."; and
394	(vi) for raw cannabis or a cannabis product sold in a vaporizer cartridge labeled on or
395	after May 3, 2023, includes a warning label that states:
396	(A) "WARNING: Vaping of cannabis-derived products has been associated with
397	lung injury."; and
398	(B) "WARNING: Inhalation of cannabis smoke has been associated with lung
399	injury.".
400	(2) To ensure that a cannabis product that a cannabis processing facility processes or
401	produces has a medical rather than recreational disposition, the facility may not produce
402	or process a product whose logo, product name, or brand name includes terms related to
403	recreational marijuana, including "weed," "pot," "reefer," "grass," "hash," "ganja,"
404	"Mary Jane," "high," "haze," "stoned," "joint," "bud," "smoke," "euphoria," "dank,"

405	"doobie," "kush," "frost," "cookies," "rec," "bake," "blunt," "combust," "bong,"
406	"budtender," "dab," "blaze," "toke," or "420."
407	(3) For any cannabis or cannabis product that the cannabis processing facility processes into
408	a gelatinous cube, gelatinous rectangular cuboid, or lozenge in a cube or rectangular
409	cuboid shape, the facility shall:
410	(a) ensure that the label described in Subsection (1)(a) does not contain a photograph or
411	other image of the content of the container; and
412	(b) include on the label described in Subsection (1)(a) a warning about the risks of
413	over-consumption.
414	(4) For any cannabis product that contains an artificially derived cannabinoid, the cannabis
415	processing facility shall ensure that the label clearly:
416	(a) identifies each artificially derived cannabinoid; and
417	(b) identifies that each artificially derived cannabinoid is an artificially derived
418	cannabinoid.
419	(5) In accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, the
420	department:
421	(a) shall make rules to establish:
422	(i) a standard labeling format that:
423	(A) complies with the requirements of this section; and
424	(B) ensures inclusion of a pharmacy label; and
425	(ii) additional requirements on packaging for cannabis and cannabis products to
426	ensure safety and product quality; and
427	(b) may make rules to further define standards regarding images, words, phrases, or
428	containers that may appeal to children under Subsection (1)(a)(v) or (1)(b)(ii).
429	Section 4. Section 4-41a-1101 is amended to read:
430	4-41a-1101 . Operating requirements General.
431	(1)(a) A medical cannabis pharmacy shall operate:
432	(i) at the physical address provided to the department under Section 4-41a-1001; and
433	(ii) in accordance with the operating plan provided to the department under Section
434	4-41a-1001 and, if applicable, Section 4-41a-1004.
435	(b) A medical cannabis pharmacy shall notify the department before a change in the
436	medical cannabis pharmacy's physical address or operating plan.
437	(2) An individual may not enter a medical cannabis pharmacy unless the individual:
438	(a) is at least 18 years old or is an emancipated minor under Section 80-7-105; and

439	(b) except as provided in Subsection (4):
440	(i) possesses a valid:
441	(A) medical cannabis pharmacy agent registration card;
442	(B) pharmacy medical provider registration card; or
443	(C) medical cannabis card;
444	(ii) is an employee of the department performing an inspection under Section
445	4-41a-1103; or
446	(iii) is another individual as the department provides.
447	(3) A medical cannabis pharmacy may not employ an individual who is younger than 21
448	years old.
449	(4) Notwithstanding Subsection (2)(a), a medical cannabis pharmacy may authorize an
450	individual who is not a medical cannabis pharmacy agent or pharmacy medical provider
451	to access the medical cannabis pharmacy if the medical cannabis pharmacy tracks and
452	monitors the individual at all times while the individual is at the medical cannabis
453	pharmacy and maintains a record of the individual's access.
454	(5) A medical cannabis pharmacy shall operate in a facility that has:
455	(a) a single, secure public entrance;
456	(b) a security system with a backup power source that:
457	(i) detects and records entry into the medical cannabis pharmacy; and
458	(ii) provides notice of an unauthorized entry to law enforcement when the medical
459	cannabis pharmacy is closed; and
460	(c) a lock on each area where the medical cannabis pharmacy stores cannabis or a
461	cannabis product.
462	(6) A medical cannabis pharmacy shall post, both clearly and conspicuously in the medical
463	cannabis pharmacy, the limit on the purchase of cannabis described in Subsection
464	4-41a-1102(2).
465	(7) Except for an emergency situation described in Subsection 26B-4-213(3)(c), a medical
466	cannabis pharmacy may not allow any individual to consume cannabis on the property
467	or premises of the medical cannabis pharmacy.
468	(8) A medical cannabis pharmacy may not sell cannabis or a cannabis product without first
469	indicating on the cannabis or cannabis product label the name of the medical cannabis
470	pharmacy.
471	(9)(a) Each medical cannabis pharmacy shall retain in the pharmacy's records the
472	following information regarding each recommendation underlying a transaction:

473	(i) the recommending medical provider's name, address, and telephone number;
474	(ii) the patient's name and address;
475	(iii) the date of issuance;
476	(iv) directions of use and dosing guidelines or an indication that the recommending
477	medical provider did not recommend specific directions of use or dosing
478	guidelines; and
479	(v) if the patient did not complete the transaction, the name of the medical cannabis
480	cardholder who completed the transaction.
481	(b)(i) Except as provided in Subsection (9)(b)(iii), a medical cannabis pharmacy may
482	not sell medical cannabis unless the medical cannabis has a label securely affixed
483	to the container indicating the following minimum information:
484	(A) the name, address, and telephone number of the medical cannabis pharmacy;
485	(B) the unique identification number that the medical cannabis pharmacy assigns;
486	(C) the date of the sale;
487	(D) the name of the patient;
488	(E) the name of the recommending medical provider who recommended the
489	medical cannabis treatment;
490	(F) directions for use and cautionary statements, if any;
491	(G) the amount dispensed and the cannabinoid content;
492	(H) the suggested use date;
493	(I) for unprocessed cannabis flower, the legal use termination date; and
494	(J) any other requirements that the department determines, in consultation with the
495	Division of Professional Licensing and the Board of Pharmacy.
496	(ii) A medical cannabis pharmacy is exempt from the requirement to provide the
497	following information under Subsection (9)(b)(i) if the information is already
498	provided on the product label that a cannabis production establishment affixes:
499	(A) a unique identification number;
500	(B) directions for use and cautionary statements;
501	(C) amount and cannabinoid content; and
502	(D) a suggested use date.
503	(iii) If the size of a medical cannabis container does not allow sufficient space to
504	include the labeling requirements described in Subsection (9)(b)(i), the medical
505	cannabis pharmacy may provide the following information described in
506	Subsection (9)(b)(i) on a supplemental label attached to the container or an

507	informational enclosure that accompanies the container:
508	(A) the cannabinoid content;
509	(B) the suggested use date; and
510	(C) any other requirements that the department determines.
511	(iv) A medical cannabis pharmacy may sell medical cannabis to another medical
512	cannabis pharmacy without a label described in Subsection (9)(b)(i).
513	(10) A pharmacy medical provider or medical cannabis pharmacy agent shall:
514	(a) upon receipt of an order from a [limited medical provider] recommending medical
515	provider in accordance with Subsections 26B-4-204(1)(b) [through (d)] and (c):
516	(i) for a written order or an electronic order under circumstances that the department
517	determines, contact the [limited medical provider] recommending medical provider
518	or the [limited medical provider's] recommending medical provider's office to
519	verify the validity of the recommendation; and
520	(ii) for an order that the pharmacy medical provider or medical cannabis pharmacy
521	agent verifies under Subsection (10)(a)(i) or an electronic order that is not subject
522	to verification under Subsection (10)(a)(i), enter the [limited medical provider's]
523	recommending medical provider's recommendation or renewal, including any
524	associated directions of use, dosing guidelines, or caregiver indication, in the state
525	electronic verification system;
526	(b) in processing an order for a holder of a conditional medical cannabis card described
527	in Subsection 26B-4-213(1)(b) that appears irregular or suspicious in the judgment of
528	the pharmacy medical provider or medical cannabis pharmacy agent, contact the
529	recommending medical provider or the recommending medical provider's office to
530	verify the validity of the recommendation before processing the cardholder's order;
531	(c) unless the medical cannabis cardholder has had a consultation under Subsection
532	26B-4-231(5), verbally offer to a medical cannabis cardholder at the time of a
533	purchase of cannabis, a cannabis product, or a medical cannabis device, personal
534	counseling with the pharmacy medical provider; and
535	(d) provide a telephone number or website by which the cardholder may contact a
536	pharmacy medical provider for counseling.
537	(11)(a) A medical cannabis pharmacy may create a medical cannabis disposal program
538	that allows an individual to deposit unused or excess medical cannabis or cannabis
539	residue from a medical cannabis device in a locked box or other secure receptacle
540	within the medical cannabis pharmacy.

541	(b) A medical cannabis pharmacy with a disposal program described in Subsection
542	(11)(a) shall ensure that only a medical cannabis pharmacy agent or pharmacy
543	medical provider can access deposited medical cannabis.
544	(c) A medical cannabis pharmacy shall dispose of any deposited medical cannabis by:
545	(i) rendering the deposited medical cannabis unusable and unrecognizable before
546	transporting deposited medical cannabis from the medical cannabis pharmacy; and
547	(ii) disposing of the deposited medical cannabis in accordance with:
548	(A) federal and state law, rules, and regulations related to hazardous waste;
549	(B) the Resource Conservation and Recovery Act, 42 U.S.C. Sec. 6991 et seq.;
550	(C) Title 19, Chapter 6, Part 5, Solid Waste Management Act; and
551	(D) other regulations that the department makes in accordance with Title 63G,
552	Chapter 3, Utah Administrative Rulemaking Act.
553	(12) A medical cannabis pharmacy:
554	(a) shall employ a pharmacist who is licensed under Title 58, Chapter 17b, Pharmacy
555	Practice Act, as a pharmacy medical provider;
556	(b) may employ a physician who has the authority to write a prescription and is licensed
557	under Title 58, Chapter 67, Utah Medical Practice Act, or Title 58, Chapter 68, Utah
558	Osteopathic Medical Practice Act, as a pharmacy medical provider;
559	(c) shall ensure that a pharmacy medical provider described in Subsection (12)(a) works
560	onsite during all business hours;
561	(d) shall designate one pharmacy medical provider described in Subsection (12)(a) as the
562	pharmacist-in-charge to oversee the operation of and generally supervise the medical
563	cannabis pharmacy; and
564	(e) shall allow the pharmacist-in-charge to determine which cannabis and cannabis
565	products the medical cannabis pharmacy maintains in the medical cannabis
566	pharmacy's inventory.
567	(13) The department shall establish by rule, in accordance with Title 63G, Chapter 3, Utah
568	Administrative Rulemaking Act, protocols for a recall of cannabis and cannabis products
569	by a medical cannabis pharmacy.
570	Section 5. Section <b>26B-1-435</b> is amended to read:
571	26B-1-435 . Medical Cannabis Policy Advisory Board creation Membership
572	Duties.
573	(1) There is created within the department the Medical Cannabis Policy Advisory Board.
574	(2)(a) The advisory board shall consist of the following members:

575	(i) appointed by the executive director:
576	(A) a [qualified medical provider] recommending medical provider who has
577	recommended medical cannabis to at least 100 patients before being appointed;
578	(B) a medical research professional;
579	(C) a mental health specialist;
580	(D) an individual who represents an organization that advocates for medical
581	cannabis patients;
582	(E) an individual who holds a medical cannabis patient card; and
583	(F) a member of the general public who does not hold a medical cannabis card; and
584	(ii) appointed by the commissioner of the Department of Agriculture and Food:
585	(A) an individual who owns or operates a licensed cannabis cultivation facility, as
586	defined in Section 4-41a-102;
587	(B) an individual who owns or operates a licensed medical cannabis pharmacy;
588	and
589	(C) a law enforcement officer.
590	(b) The commissioner of the Department of Agriculture and Food shall ensure that at
591	least one individual appointed under Subsection (2)(a)(ii)(A) or (B) also owns or
592	operates a licensed cannabis processing facility.
593	(3)(a) Subject to Subsection (3)(b), a member of the advisory board shall serve for a four
594	year term.
595	(b) When appointing the initial membership of the advisory board, the executive director
596	and the commissioner of the Department of Agriculture and Food shall coordinate to
597	appoint four advisory board members to serve a term of two years to ensure that
598	approximately half of the board is appointed every two years.
599	(4)(a) If an advisory board member is no longer able to serve as a member, a new
600	member shall be appointed in the same manner as the original appointment.
601	(b) A member appointed in accordance with Subsection (4)(a) shall serve for the
602	remainder of the unexpired term of the original appointment.
603	(5)(a) A majority of the advisory board members constitutes a quorum.
604	(b) The action of a majority of a quorum constitutes an action of the advisory board.
605	(c) For a term lasting one year, the advisory board shall annually designate members of
606	the advisory board to serve as chair and vice-chair.
607	(d) When designating the chair and vice-chair, the advisory board shall ensure that at
608	least one individual described Subsection (2)(a)(i) is appointed as chair or vice-chair.

609 (6) An advisory board member may not receive compensation or benefits for the member's 610 service on the advisory board but may receive per diem and reimbursement for travel 611 expenses incurred as an advisory board member in accordance with: 612 (a) Sections 63A-3-106 and 63A-3-107; and 613 (b) rules made by the Division of Finance pursuant to Sections 63A-3-106 and 614 63A-3-107. 615 (7) The department shall: 616 (a) provide staff support for the advisory board; and 617 (b) assist the advisory board in conducting meetings. 618 (8) The advisory board may recommend: 619 (a) to the department or the Department of Agriculture and Food changes to current or 620 proposed medical cannabis rules or statutes; or 621 (b) to the appropriate legislative committee whether the advisory board supports a 622 change to medical cannabis statutes. 623 (9) The advisory board shall: 624 (a) review any draft rule that is authorized under this chapter or Title 4, Chapter 41a, 625 Cannabis Production Establishments and Pharmacies: 626 (b) consult with the Department of Agriculture and Food regarding the issuance of an 627 additional: 628 (i) cultivation facility license under Section 4-41a-205; or 629 (ii) pharmacy license under Section 4-41a-1005; 630 (c) consult with the department regarding cannabis patient education; 631 (d) consult regarding the reasonableness of any fees set by the department or the 632 Department of Agriculture and Food that pertain to the medical cannabis program; 633 and 634 (e) consult regarding any issue pertaining to medical cannabis when asked by the 635 department or the Utah Department of Agriculture and Food. 636 Section 6. Section 26B-4-201 is amended to read: 637 26B-4-201. Definitions. 638 As used in this part: 639 (1) "Active tetrahydrocannabinol" means THC, any THC analog, and 640 tetrahydrocannabinolic acid. 641 (2) "Administration of criminal justice" means the performance of detection, apprehension, 642 detention, pretrial release, post-trial release, prosecution, and adjudication.

643	(3) "Advertise" means information provided by a person in any medium:
644	(a) to the public; and
645	(b) that is not age restricted to an individual who is at least 21 years old.
646	(4) "Advisory board" means the Medical Cannabis Policy Advisory Board created in
647	Section 26B-1-435.
648	(5) "Cannabis Research Review Board" means the Cannabis Research Review Board
649	created in Section 26B-1-420.
650	(6) "Cannabis" means marijuana.
651	(7) "Cannabis processing facility" means the same as that term is defined in Section
652	4-41a-102.
653	(8) "Cannabis product" means a product that:
654	(a) is intended for human use; and
655	(b) contains cannabis or any tetrahydrocannabinol or THC analog in a total
656	concentration of 0.3% or greater on a dry weight basis.
657	(9) "Cannabis production establishment" means the same as that term is defined in Section
658	4-41a-102.
659	(10) "Cannabis production establishment agent" means the same as that term is defined in
660	Section 4-41a-102.
661	(11) "Cannabis production establishment agent registration card" means the same as that
662	term is defined in Section 4-41a-102.
663	(12) "Conditional medical cannabis card" means an electronic medical cannabis card that
664	the department issues in accordance with Subsection 26B-4-213(1)(b) to allow an
665	applicant for a medical cannabis card to access medical cannabis during the department's
666	review of the application.
667	(13) "Controlled substance database" means the controlled substance database created in
668	Section 58-37f-201.
669	(14) "Delivery address" means the same as that term is defined in Section 4-41a-102.
670	(15) "Department" means the Department of Health and Human Services.
671	(16) "Designated caregiver" means:
672	(a) an individual:
673	(i) whom an individual with a medical cannabis patient card or a medical cannabis
674	guardian card designates as the patient's caregiver; and
675	(ii) who registers with the department under Section 26B-4-214; or
676	(b)(i) a facility that an individual designates as a designated caregiver in accordance

677	with Subsection 26B-4-214(1)(b); or
678	(ii) an assigned employee of the facility described in Subsection 26B-4-214(1)(b)(ii).
679	(17) "Directions of use" means recommended routes of administration for a medical
680	cannabis treatment and suggested usage guidelines.
681	(18) "Dosing guidelines" means a quantity range and frequency of administration for a
682	recommended treatment of medical cannabis.
683	(19) "Government issued photo identification" means any of the following forms of
684	identification:
685	(a) a valid state-issued driver license or identification card;
686	(b) a valid United States federal-issued photo identification, including:
687	(i) a United States passport;
688	(ii) a United States passport card;
689	(iii) a United States military identification card; or
690	(iv) a permanent resident card or alien registration receipt card; or
691	(c) a foreign passport.
692	(20) "Home delivery medical cannabis pharmacy" means a medical cannabis pharmacy that
693	the department authorizes, as part of the pharmacy's license, to deliver medical cannabis
694	shipments to a delivery address to fulfill electronic orders that the state central patient
695	portal facilitates.
696	(21) "Inventory control system" means the system described in Section 4-41a-103.
697	(22) "Legal dosage limit" means an amount that:
698	(a) is sufficient to provide 30 days of treatment based on the dosing guidelines that the
699	relevant recommending medical provider or the state central patient portal or
700	pharmacy medical provider, in accordance with Subsection 26B-4-230(5),
701	recommends; and
702	(b) may not exceed:
703	(i) for unprocessed cannabis in a medicinal dosage form, 113 grams by weight; and
704	(ii) for a cannabis product in a medicinal dosage form, a quantity that contains, in
705	total, greater than 20 grams of active tetrahydrocannabinol.
706	(23) "Legal use termination date" means a date on the label of a container of unprocessed
707	cannabis flower:
708	(a) that is 60 days after the date of purchase of the cannabis; and
709	(b) after which, the cannabis is no longer in a medicinal dosage form outside of the
710	primary residence of the relevant medical cannabis patient cardholder.

711	[(24) "Limited medical provider" means an individual who:]
712	[(a) meets the recommending qualifications; and]
713	[(b) has no more than 15 patients with a valid medical cannabis patient card as a result
714	of the individual's recommendation, in accordance with Subsection 26B-4-204(1)(b).]
715	[(25)] (24) "Marijuana" means the same as that term is defined in Section 58-37-2.
716	[(26)] (25) "Medical cannabis" means cannabis in a medicinal dosage form or a cannabis
717	product in a medicinal dosage form.
718	[(27)] (26) "Medical cannabis card" means a medical cannabis patient card, a medical
719	cannabis guardian card, a medical cannabis caregiver card, or a conditional medical
720	cannabis card.
721	[(28)] (27) "Medical cannabis cardholder" means:
722	(a) a holder of a medical cannabis card; or
723	(b) a facility or assigned employee, described in Subsection (16)(b), only:
724	(i) within the scope of the facility's or assigned employee's performance of the role of
725	a medical cannabis patient cardholder's caregiver designation under Subsection
726	26B-4-214(1)(b); and
727	(ii) while in possession of documentation that establishes:
728	(A) a caregiver designation described in Subsection 26B-4-214(1)(b);
729	(B) the identity of the individual presenting the documentation; and
730	(C) the relation of the individual presenting the documentation to the caregiver
731	designation.
732	[(29)] (28) "Medical cannabis caregiver card" means an electronic document that a
733	cardholder may print or store on an electronic device or a physical card or document that:
734	(a) the department issues to an individual whom a medical cannabis patient cardholder
735	or a medical cannabis guardian cardholder designates as a designated caregiver; and
736	(b) is connected to the electronic verification system.
737	[(30)] (29) "Medical cannabis courier" means the same as that term is defined in Section
738	4-41a-102.
739	[(31)] (30)(a) "Medical cannabis device" means a device that an individual uses to ingest
740	or inhale cannabis in a medicinal dosage form or a cannabis product in a medicinal
741	dosage form.
742	(b) "Medical cannabis device" does not include a device that:
743	(i) facilitates cannabis combustion; or
744	(ii) an individual uses to ingest substances other than cannabis.

745	[(32)] (31) "Medical cannabis guardian card" means an electronic document that a
746	cardholder may print or store on an electronic device or a physical card or document that:
747	(a) the department issues to the parent or legal guardian of a minor with a qualifying
748	condition; and
749	(b) is connected to the electronic verification system.
750	[(33)] (32) "Medical cannabis patient card" means an electronic document that a cardholder
751	may print or store on an electronic device or a physical card or document that:
752	(a) the department issues to an individual with a qualifying condition; and
753	(b) is connected to the electronic verification system.
754	[(34)] (33) "Medical cannabis pharmacy" means a person that:
755	(a)(i) acquires or intends to acquire medical cannabis or a cannabis product in a
756	medicinal dosage form from a cannabis processing facility or another medical
757	cannabis pharmacy or a medical cannabis device; or
758	(ii) possesses medical cannabis or a medical cannabis device; and
759	(b) sells or intends to sell medical cannabis or a medical cannabis device to a medical
760	cannabis cardholder.
761	[(35)] (34) "Medical cannabis pharmacy agent" means an individual who holds a valid
762	medical cannabis pharmacy agent registration card issued by the department.
763	[(36)] (35) "Medical cannabis pharmacy agent registration card" means a registration card
764	issued by the department that authorizes an individual to act as a medical cannabis
765	pharmacy agent.
766	[(37)] (36) "Medical cannabis shipment" means the same as that term is defined in Section
767	4-41a-102.
768	[(38)] (37) "Medical cannabis treatment" means cannabis in a medicinal dosage form, a
769	cannabis product in a medicinal dosage form, or a medical cannabis device.
770	[(39)] (38)(a) "Medicinal dosage form" means:
771	(i) for processed medical cannabis, the following with a specific and consistent
772	cannabinoid content:
773	(A) a tablet;
774	(B) a capsule;
775	(C) a concentrated liquid or viscous oil;
776	(D) a liquid suspension that does not exceed 30 milliliters;
777	(E) a topical preparation;
778	(F) a transdermal preparation;

779	(G) a sublingual preparation;
780	(H) a gelatinous cube, gelatinous rectangular cuboid, or lozenge in a cube or
781	rectangular cuboid shape;
782	(I) a resin or wax;
783	(J) an aerosol;
784	(K) a suppository preparation; or
785	(L) a soft or hard confection that is a uniform rectangular cuboid or uniform
786	spherical shape, is homogeneous in color and texture, and each piece is a single
787	serving; or
788	(ii) for unprocessed cannabis flower, a container described in Section 4-41a-602 that:
789	(A) contains cannabis flower in a quantity that varies by no more than 10% from
790	the stated weight at the time of packaging;
791	(B) at any time the medical cannabis cardholder transports or possesses the
792	container in public, is contained within an opaque bag or box that the medical
793	cannabis pharmacy provides; and
794	(C) is labeled with the container's content and weight, the date of purchase, the
795	legal use termination date, and a barcode that provides information connected
796	to an inventory control system.
797	(b) "Medicinal dosage form" includes a portion of unprocessed cannabis flower that:
798	(i) the medical cannabis cardholder has recently removed from the container
799	described in Subsection [ <del>(39)(a)(ii)</del> ] ( <u>38)(a)(ii)</u> for use; and
800	(ii) does not exceed the quantity described in Subsection $[(39)(a)(ii)]$ (38)(a)(ii).
801	(c) "Medicinal dosage form" does not include:
802	(i) any unprocessed cannabis flower outside of the container described in Subsection [
803	(39)(a)(ii)] (38)(a)(ii), except as provided in Subsection [(39)(b)] (38)(b);
804	(ii) any unprocessed cannabis flower in a container described in Subsection [
805	(39)(a)(ii)] (38)(a)(ii) after the legal use termination date;
806	(iii) a process of vaporizing and inhaling concentrated cannabis by placing the
807	cannabis on a nail or other metal object that is heated by a flame, including a
808	blowtorch;
809	(iv) a liquid suspension that is branded as a beverage;
810	(v) a substance described in Subsection $[(39)(a)(i)] (38)(a)(i)$ or (ii) if the substance is
811	not measured in grams, milligrams, or milliliters; or
812	(vi) a substance that contains or is covered to any degree with chocolate.

813	[(40)] (39) "Nonresident patient" means an individual who:
814	(a) is not a resident of Utah or has been a resident of Utah for less than 45 days;
815	(b) has a currently valid medical cannabis card or the equivalent of a medical cannabis
816	card under the laws of another state, district, territory, commonwealth, or insular
817	possession of the United States; and
818	(c) has been diagnosed with a qualifying condition as described in Section 26B-4-203.
819	[(41)] (40) "Pharmacy medical provider" means the medical provider required to be on site
820	at a medical cannabis pharmacy under Section 26B-4-219.
821	[(42)] (41) "Provisional patient card" means a card that:
822	(a) the department issues to a minor with a qualifying condition for whom:
823	(i) a recommending medical provider has recommended a medical cannabis
824	treatment; and
825	(ii) the department issues a medical cannabis guardian card to the minor's parent or
826	legal guardian; and
827	(b) is connected to the electronic verification system.
828	[(43) "Qualified medical provider" means an individual:]
829	[(a) who meets the recommending qualifications; and]
830	[(b) whom the department registers to recommend treatment with cannabis in a
831	medicinal dosage form under Section 26B-4-204.]
832	[(44)] (42) "Qualified Patient Enterprise Fund" means the enterprise fund created in Section
832 833	[(44)] (42) "Qualified Patient Enterprise Fund" means the enterprise fund created in Section 26B-1-310.
833	26B-1-310.
833 834	26B-1-310. [ <del>(45)</del> ] <u>(43)</u> "Qualifying condition" means a condition described in Section 26B-4-203.
833 834 835	<ul> <li>26B-1-310.</li> <li>[(45)] (43) "Qualifying condition" means a condition described in Section 26B-4-203.</li> <li>[(46)] (44) "Recommend" or "recommendation" means, for a recommending medical</li> </ul>
833 834 835 836	<ul> <li>26B-1-310.</li> <li>[(45)] (43) "Qualifying condition" means a condition described in Section 26B-4-203.</li> <li>[(46)] (44) "Recommend" or "recommendation" means, for a recommending medical provider, the act of suggesting the use of medical cannabis treatment, which:</li> </ul>
833 834 835 836 837	<ul> <li>26B-1-310.</li> <li>[(45)] (43) "Qualifying condition" means a condition described in Section 26B-4-203.</li> <li>[(46)] (44) "Recommend" or "recommendation" means, for a recommending medical provider, the act of suggesting the use of medical cannabis treatment, which:</li> <li>(a) certifies the patient's eligibility for a medical cannabis card; and</li> </ul>
833 834 835 836 837 838	<ul> <li>26B-1-310.</li> <li>[(45)] (43) "Qualifying condition" means a condition described in Section 26B-4-203.</li> <li>[(46)] (44) "Recommend" or "recommendation" means, for a recommending medical provider, the act of suggesting the use of medical cannabis treatment, which: <ul> <li>(a) certifies the patient's eligibility for a medical cannabis card; and</li> <li>(b) may include, at the recommending medical provider's discretion, directions of use,</li> </ul> </li> </ul>
833 834 835 836 837 838 839	<ul> <li>26B-1-310.</li> <li>[(45)] (43) "Qualifying condition" means a condition described in Section 26B-4-203.</li> <li>[(46)] (44) "Recommend" or "recommendation" means, for a recommending medical provider, the act of suggesting the use of medical cannabis treatment, which: <ul> <li>(a) certifies the patient's eligibility for a medical cannabis card; and</li> <li>(b) may include, at the recommending medical provider's discretion, directions of use, with or without dosing guidelines.</li> </ul> </li> </ul>
<ul> <li>833</li> <li>834</li> <li>835</li> <li>836</li> <li>837</li> <li>838</li> <li>839</li> <li>840</li> </ul>	<ul> <li>26B-1-310.</li> <li>[(45)] (43) "Qualifying condition" means a condition described in Section 26B-4-203.</li> <li>[(46)] (44) "Recommend" or "recommendation" means, for a recommending medical provider, the act of suggesting the use of medical cannabis treatment, which: <ul> <li>(a) certifies the patient's eligibility for a medical cannabis card; and</li> <li>(b) may include, at the recommending medical provider's discretion, directions of use, with or without dosing guidelines.</li> </ul> </li> <li>[(47)] (45) "Recommending medical provider" [means a qualified medical provider or a</li> </ul>
<ul> <li>833</li> <li>834</li> <li>835</li> <li>836</li> <li>837</li> <li>838</li> <li>839</li> <li>840</li> <li>841</li> </ul>	<ul> <li>26B-1-310.</li> <li>[(45)] (43) "Qualifying condition" means a condition described in Section 26B-4-203.</li> <li>[(46)] (44) "Recommend" or "recommendation" means, for a recommending medical provider, the act of suggesting the use of medical cannabis treatment, which: <ul> <li>(a) certifies the patient's eligibility for a medical cannabis card; and</li> <li>(b) may include, at the recommending medical provider's discretion, directions of use, with or without dosing guidelines.</li> </ul> </li> <li>[(47)] (45) "Recommending medical provider" [means a qualified medical provider or a limited medical provider] means an individual who meets the recommending qualifications.</li> <li>[(48)] (46) "Recommending qualifications" means that an individual:</li> </ul>
<ul> <li>833</li> <li>834</li> <li>835</li> <li>836</li> <li>837</li> <li>838</li> <li>839</li> <li>840</li> <li>841</li> <li>842</li> </ul>	<ul> <li>26B-1-310.</li> <li>[(45)] (43) "Qualifying condition" means a condition described in Section 26B-4-203.</li> <li>[(46)] (44) "Recommend" or "recommendation" means, for a recommending medical provider, the act of suggesting the use of medical cannabis treatment, which: <ul> <li>(a) certifies the patient's eligibility for a medical cannabis card; and</li> <li>(b) may include, at the recommending medical provider's discretion, directions of use, with or without dosing guidelines.</li> </ul> </li> <li>[(47)] (45) "Recommending medical provider" [means a qualified medical provider or a limited medical provider] means an individual who meets the recommending qualifications.</li> </ul>
<ul> <li>833</li> <li>834</li> <li>835</li> <li>836</li> <li>837</li> <li>838</li> <li>839</li> <li>840</li> <li>841</li> <li>842</li> <li>843</li> </ul>	<ul> <li>26B-1-310.</li> <li>[(45)] (43) "Qualifying condition" means a condition described in Section 26B-4-203.</li> <li>[(46)] (44) "Recommend" or "recommendation" means, for a recommending medical provider, the act of suggesting the use of medical cannabis treatment, which: <ul> <li>(a) certifies the patient's eligibility for a medical cannabis card; and</li> <li>(b) may include, at the recommending medical provider's discretion, directions of use, with or without dosing guidelines.</li> </ul> </li> <li>[(47)] (45) "Recommending medical provider" [means a qualified medical provider or a limited medical provider] means an individual who meets the recommending qualifications.</li> <li>[(48)] (46) "Recommending qualifications" means that an individual:</li> </ul>

847	(iii) possesses the authority, in accordance with the individual's scope of practice, to
848	prescribe a Schedule II controlled substance; and
849	(b) is licensed as:
850	(i) a podiatrist under Title 58, Chapter 5a, Podiatric Physician Licensing Act;
851	(ii) an advanced practice registered nurse under Title 58, Chapter 31b, Nurse Practice
852	Act;
853	(iii) a physician under Title 58, Chapter 67, Utah Medical Practice Act, or Title 58,
854	Chapter 68, Utah Osteopathic Medical Practice Act; or
855	(iv) a physician assistant under Title 58, Chapter 70a, Utah Physician Assistant Act.
856	[(49)] (47) "State central patient portal" means the website the department creates, in
857	accordance with Section 26B-4-236, to facilitate patient safety, education, and an
858	electronic medical cannabis order.
859	[(50)] (48) "State electronic verification system" means the system described in Section
860	26B-4-202.
861	[(51)] (49) "Targeted marketing" means the promotion by a [qualified medical provider]
862	recommending medical provider, medical clinic, or medical office that employs a [
863	qualified medical provider] recommending medical provider of a medical cannabis
864	recommendation service using any of the following methods:
865	(a) electronic communication to an individual who is at least 21 years old and has
866	requested to receive promotional information;
867	(b) an in-person marketing event that is held in an area where only an individual who is
868	at least 21 years old may access the event;
869	(c) other marketing material that is physically or digitally displayed in the office of the
870	medical clinic or office that employs a [qualified medical provider] recommending
871	medical provider; or
872	(d) a leaflet that a [qualified medical provider] recommending medical provider, medical
873	clinic, or medical office that employs a [qualified medical provider] recommending
874	medical provider shares with an individual who is at least 21 years old.
875	[(52)] (50) "Tetrahydrocannabinol" or "THC" means a substance derived from cannabis or a
876	synthetic equivalent as described in Subsection 58-37-4(2)(a)(iii)(AA).
877	[(53)] (51) "THC analog" means the same as that term is defined in Section 4-41-102.
878	Section 7. Section <b>26B-4-202</b> is amended to read:
879	26B-4-202 . Electronic verification system.
880	(1) The Department of Agriculture and Food, the department, the Department of Public

881	Safety, and the Division of Technology Services shall:
882	(a) enter into a memorandum of understanding in order to determine the function and
883	operation of the state electronic verification system in accordance with Subsection (2);
884	(b) coordinate with the Division of Purchasing, under Title 63G, Chapter 6a, Utah
885	Procurement Code, to develop a request for proposals for a third-party provider to
886	develop and maintain the state electronic verification system in coordination with the
887	Division of Technology Services; and
888	(c) select a third-party provider who:
889	(i) meets the requirements contained in the request for proposals issued under
890	Subsection (1)(b); and
891	(ii) may not have any commercial or ownership interest in a cannabis production
892	establishment or a medical cannabis pharmacy.
893	(2) The Department of Agriculture and Food, the department, the Department of Public
894	Safety, and the Division of Technology Services shall ensure that the state electronic
895	verification system described in Subsection (1):
896	(a) allows an individual to apply for a medical cannabis patient card or, if applicable, a
897	medical cannabis guardian card, provided that the card may not become active until:
898	(i) the relevant [qualified medical provider] recommending medical provider
899	completes the associated medical cannabis recommendation; or
900	(ii) [for a medical cannabis card related to a limited medical provider's
901	recommendation, ]the medical cannabis pharmacy completes the recording
902	described in Subsection (2)(d);
903	(b) allows an individual to apply to renew a medical cannabis patient card or a medical
904	cannabis guardian card in accordance with Section 26B-4-213;
905	(c) allows a [qualified medical provider] recommending medical provider, or an
906	employee described in Subsection (3) acting on behalf of the [qualified medical
907	provider] recommending medical provider, to:
908	(i) access dispensing and card status information regarding a patient:
909	(A) with whom the [qualified medical provider] recommending medical provider
910	has a provider-patient relationship; and
911	(B) for whom the [qualified medical provider] recommending medical provider
912	has recommended or is considering recommending a medical cannabis card;
913	(ii) electronically recommend treatment with cannabis in a medicinal dosage form or
914	a cannabis product in a medicinal dosage form and optionally recommend dosing

915	guidelines;
916	(iii) electronically renew a recommendation to a medical cannabis patient cardholder
917	or medical cannabis guardian cardholder:
918	(A) using telehealth services, for the [qualified medical provider] recommending
919	medical provider who originally recommended a medical cannabis treatment
920	during a face-to-face visit with the patient; or
921	(B) during a face-to-face visit with the patient, for a [qualified medical provider]
922	recommending medical provider who did not originally recommend the
923	medical cannabis treatment during a face-to-face visit; and
924	(iv) submit an initial application, renewal application, or application payment on
925	behalf of an individual applying for any of the following:
926	(A) a medical cannabis patient card;
927	(B) a medical cannabis guardian card; or
928	(C) a medical cannabis caregiver card;
929	(d) allows a medical cannabis pharmacy medical provider or medical cannabis pharmacy
930	agent, in accordance with Subsection 4-41a-1101(10)(a), to:
931	(i) access the electronic verification system to review the history within the system of
932	a patient with whom the provider or agent is interacting, limited to read-only
933	access for medical cannabis pharmacy agents unless the medical cannabis
934	pharmacy's pharmacist in charge authorizes add and edit access;
935	(ii) record a patient's recommendation from a [limited medical provider]
936	recommending medical provider, including any directions of use, dosing
937	guidelines, or caregiver indications from the [limited medical provider]
938	recommending medical provider;
939	(iii) record a [limited medical provider's] recommending medical provider's renewal
940	of the provider's previous recommendation; and
941	(iv) submit an initial application, renewal application, or application payment on
942	behalf of an individual applying for any of the following:
943	(A) a medical cannabis patient card;
944	(B) a medical cannabis guardian card; or
945	(C) a medical cannabis caregiver card;
946	(e) connects with:
947	(i) an inventory control system that a medical cannabis pharmacy uses to track in real
948	time and archive purchases of any cannabis in a medicinal dosage form, cannabis

949	product in a medicinal dosage form, or a medical cannabis device, including:
950	(A) the time and date of each purchase;
951	(B) the quantity and type of cannabis, cannabis product, or medical cannabis
952	device purchased;
953	(C) any cannabis production establishment, any medical cannabis pharmacy, or
954	any medical cannabis courier associated with the cannabis, cannabis product,
955	or medical cannabis device; and
956	(D) the personally identifiable information of the medical cannabis cardholder
957	who made the purchase; and
958	(ii) any commercially available inventory control system that a cannabis production
959	establishment utilizes in accordance with Section 4-41a-103 to use data that the
960	Department of Agriculture and Food requires by rule, in accordance with Title
961	63G, Chapter 3, Utah Administrative Rulemaking Act, from the inventory
962	tracking system that a licensee uses to track and confirm compliance;
963	(f) provides access to:
964	(i) the department to the extent necessary to carry out the department's functions and
965	responsibilities under this part;
966	(ii) the Department of Agriculture and Food to the extent necessary to carry out the
967	functions and responsibilities of the Department of Agriculture and Food under
968	Title 4, Chapter 41a, Cannabis Production Establishments and Pharmacies; and
969	(iii) the Division of Professional Licensing to the extent necessary to carry out the
970	functions and responsibilities related to the participation of the following in the
971	recommendation and dispensing of medical cannabis:
972	(A) a podiatrist licensed under Title 58, Chapter 5a, Podiatric Physician Licensing
973	Act;
974	(B) a pharmacist licensed under Title 58, Chapter 17b, Pharmacy Practice Act;
975	(C) an advanced practice registered nurse licensed under Title 58, Chapter 31b,
976	Nurse Practice Act;
977	(D) a physician licensed under Title 58, Chapter 67, Utah Medical Practice Act, or
978	Title 58, Chapter 68, Utah Osteopathic Medical Practice Act; or
979	(E) a physician assistant licensed under Title 58, Chapter 70a, Utah Physician
980	Assistant Act;
981	(g) provides access to and interaction with the state central patient portal;
982	(h) communicates dispensing information from a record that a medical cannabis

983	pharmacy submits to the state electronic verification system under Subsection
984	4-41a-1102(3)(a)(ii) to the controlled substance database;
985	(i) provides access to state or local law enforcement only to verify the validity of an
986	individual's medical cannabis card for the administration of criminal justice and
987	through a database used by law enforcement; and
988	(j) creates a record each time a person accesses the system that identifies the person who
989	accesses the system and the individual whose records the person accesses.
990	(3)(a) An employee of a [qualified medical provider] recommending medical provider
991	may access the electronic verification system for a purpose described in Subsection
992	(2)(c) on behalf of the [qualified medical provider] recommending medical provider if:
993	(i) the [qualified medical provider] recommending medical provider has designated
994	the employee as an individual authorized to access the electronic verification
995	system on behalf of the [qualified medical provider] recommending medical
996	provider;
997	(ii) the [qualified medical provider] recommending medical provider provides written
998	notice to the department of the employee's identity and the designation described
999	in Subsection (3)(a)(i); and
1000	(iii) the department grants to the employee access to the electronic verification
1001	system.
1002	(b) An employee of a business that employs a [qualified medical provider]
1003	recommending medical provider may access the electronic verification system for a
1004	purpose described in Subsection (2)(c) on behalf of the [qualified medical provider]
1005	recommending medical provider if:
1006	(i) the [qualified medical provider] recommending medical provider has designated
1007	the employee as an individual authorized to access the electronic verification
1008	system on behalf of the [qualified medical provider] recommending medical
1009	provider;
1010	(ii) the [qualified medical provider] recommending medical provider and the
1011	employing business jointly provide written notice to the department of the
1012	employee's identity and the designation described in Subsection (3)(b)(i); and
1013	(iii) the department grants to the employee access to the electronic verification
1014	system.
1015	(4)(a) As used in this Subsection (4), "prescribing provider" means:
1016	(i) a podiatrist licensed under Title 58, Chapter 5a, Podiatric Physician Licensing Act;

1017	(ii) an advanced practice registered nurse licensed under Title 58, Chapter 31b, Nurse
1018	Practice Act;
1019	(iii) a physician licensed under Title 58, Chapter 67, Utah Medical Practice Act, or
1020	Title 58, Chapter 68, Utah Osteopathic Medical Practice Act; or
1021	(iv) a physician assistant licensed under Title 58, Chapter 70a, Utah Physician
1022	Assistant Act.
1023	(b) A prescribing provider may access information in the electronic verification system
1024	regarding a patient the prescribing provider treats.
1025	(5) The department may release limited data that the system collects for the purpose of:
1026	(a) conducting medical and other department approved research;
1027	(b) providing the report required by Section 26B-4-222; and
1028	(c) other official department purposes.
1029	(6) The department shall make rules, in accordance with Title 63G, Chapter 3, Utah
1030	Administrative Rulemaking Act, to establish:
1031	(a) the limitations on access to the data in the state electronic verification system as
1032	described in this section; and
1033	(b) standards and procedures to ensure accurate identification of an individual requesting
1034	information or receiving information in this section.
1035	(7) Any person who negligently or recklessly releases any information in the state
1036	electronic verification system in violation of this section is guilty of a class C
1037	misdemeanor.
1038	(8) Any person who obtains or attempts to obtain information from the state electronic
1039	verification system by misrepresentation or fraud is guilty of a third degree felony.
1040	(9)(a) Except as provided in Subsections (9)(c) and (9)(e), a person may not knowingly
1041	and intentionally use, release, publish, or otherwise make available to any other
1042	person information obtained from the state electronic verification system for any
1043	purpose other than a purpose specified in this section.
1044	(b) Each separate violation of this Subsection (9) is:
1045	(i) a third degree felony; and
1046	(ii) subject to a civil penalty not to exceed \$5,000.
1047	(c) A law enforcement officer who uses the database used by law enforcement to access
1048	information in the electronic verification system for a reason that is not the
1049	administration of criminal justice is guilty of a class B misdemeanor.
1050	(d) The department shall determine a civil violation of this Subsection (9) in accordance

1051	with Title 63G, Chapter 4, Administrative Procedures Act.
1052	(e) Civil penalties assessed under this Subsection (9) shall be deposited into the General
1053	Fund.
1054	(f) This Subsection (9) does not prohibit a person who obtains information from the state
1055	electronic verification system under Subsection (2)(a), (c), or (f) from:
1056	(i) including the information in the person's medical chart or file for access by a
1057	person authorized to review the medical chart or file;
1058	(ii) providing the information to a person in accordance with the requirements of the
1059	Health Insurance Portability and Accountability Act of 1996; or
1060	(iii) discussing or sharing that information about the patient with the patient.
1061	Section 8. Section <b>26B-4-203</b> is amended to read:
1062	26B-4-203 . Qualifying condition.
1063	(1) By designating a particular condition under Subsection (2) for which the use of medical
1064	cannabis to treat symptoms is decriminalized, the Legislature does not conclusively state
1065	that:
1066	(a) current scientific evidence clearly supports the efficacy of a medical cannabis
1067	treatment for the condition; or
1068	(b) a medical cannabis treatment will treat, cure, or positively affect the condition.
1069	(2) For the purposes of this part, each of the following conditions is a qualifying condition:
1070	(a) HIV or acquired immune deficiency syndrome;
1071	(b) Alzheimer's disease;
1072	(c) amyotrophic lateral sclerosis;
1073	(d) cancer;
1074	(e) cachexia;
1075	(f) persistent nausea that is not significantly responsive to traditional treatment, except
1076	for nausea related to:
1077	(i) pregnancy;
1078	(ii) cannabis-induced cyclical vomiting syndrome; or
1079	(iii) cannabinoid hyperemesis syndrome;
1080	(g) Crohn's disease or ulcerative colitis;
1081	(h) epilepsy or debilitating seizures;
1082	(i) multiple sclerosis or persistent and debilitating muscle spasms;
1083	(j) post-traumatic stress disorder that is being treated and monitored by a licensed mental
1084	health therapist, as that term is defined in Section 58-60-102, and that:

1086       or contracted by the United States Veterans Administration, evidenced by copies         1087       of medical records from the United States Veterans Administration that are         1088       included as part of the [qualified medical provider's] recommending medical         1089       provider's pre-treatment assessment and medical record documentation; or         1090       (ii) has been diagnosed or confirmed, through face-to-face or telehealth evaluation of         1091       the patient, by a provider who is:         1092       (A) a licensed board-eligible or board-certified psychiatrist;         1093       (B) a licensed board-eligible or board-certified psychiatrist;         1093       (B) a licensed psychologist with a master's-level degree;         1094       (C) a licensed clinical social worker with a master's-level degree;         1095       (D) a licensed advanced practice registered nurse who is qualified to practice         1096       within the psychiatric mental health nursing, specialty and who has completed         1097       the clinical practice requirements in psychiatric mental health nursing, including in psychotherapy, in accordance with Subsection 58-31b-302(5)(g);         1099       or         1100       (E) a licensed physician assistant who is qualified to specialize in mental health         1101       care under Section 58-70a-501.1;         1102       (k) autism;	1085	(i) has been diagnosed by a healthcare provider or mental health provider employed
1088included as part of the [qualified-medical provider's] recommending medical1089provider's pre-treatment assessment and medical record documentation; or1090(ii) has been diagnosed or confirmed, through face-to-face or telehealth evaluation of1091the patient, by a provider who is:1092(A) a licensed board-eligible or board-certified psychiatrist;1093(B) a licensed board-eligible or board-certified psychiatrist;1094(C) a licensed clinical social worker with a master's-level degree;1095(D) a licensed advanced practice registered nurse who is qualified to practice1096within the psychiatric mental health nursing specialty and who has completed1097the clinical practice requirements in psychiatric mental health nursing,1098including in psychotherapy, in accordance with Subsection 58-31b-302(5)(g);1099or1100(E) a licensed physician assistant who is qualified to specialize in mental health1101care under Section 58-70a-501.1;1102(k) autism;1103(I) a terminal illness when the patient's remaining life expectancy is less than six months;1104(m) a condition resulting in the individual receiving hospice care;1105(a) affects less than 200,000 individuals in the United States, as defined in Section1107526 of the Federal Food, Drug, and Cosmetic Act; and1108(ii) is not adequately managed despite treatment attempts using:1106(b) physical interventions;1111(c) pain lasting longer than two weeks that is not adequately managed, in the [qualified	1086	or contracted by the United States Veterans Administration, evidenced by copies
1089         provider's pre-treatment assessment and medical record documentation; or           1090         (ii) has been diagnosed or confirmed, through face-to-face or telehealth evaluation of           1091         the patient, by a provider who is:           1092         (A) a licensed board-eligible or board-certified psychiatrist;           1093         (B) a licensed psychologist with a master's-level degree;           1094         (C) a licensed clinical social worker with a master's-level degree;           1095         (D) a licensed advanced practice registered nurse who is qualified to practice           1096         within the psychiatric mental health nursing specialty and who has completed           1097         the clinical practice requirements in psychiatric mental health nursing,           1098         including in psychotherapy, in accordance with Subsection 58-31b-302(5)(g);           1099         or           1100         (E) a licensed physician assistant who is qualified to specialize in mental health           1010         care under Section 58-70a-501.1;           1102         (k) autism;           1103         (I) a terminal illness when the patient's remaining life expectancy is less than six months;           1104         care under Section 58-70a-501.1;           1105         (n) a condition or disease that:           1106         (i) affects less than 200,000 indivi	1087	of medical records from the United States Veterans Administration that are
1090       (ii) has been diagnosed or confirmed, through face-to-face or telehealth evaluation of         1091       the patient, by a provider who is:         1092       (A) a licensed board-eligible or board-certified psychiatrist;         1093       (B) a licensed psychologist with a master's-level degree;         1094       (C) a licensed clinical social worker with a master's-level degree;         1095       (D) a licensed advanced practice registered nurse who is qualified to practice         1096       within the psychiatric mental health nursing specialty and who has completed         1097       the clinical practice requirements in psychiatric mental health nursing,         1098       including in psychotherapy, in accordance with Subsection 58-31b-302(5)(g);         1099       or         1100       (E) a licensed physician assistant who is qualified to specialize in mental health         1101       care under Section 58-70a-501.1;         1102       (k) autism;         1103       (1) a terminal illness when the patient's remaining life expectancy is less than six months;         1104       (m) a condition resulting in the individual receiving hospice care;         1105       (n) a arae condition or disease that:         1106       (i) affects less than 200,000 individuals in the United States, as defined in Section         1107       526 of the Federal Food, Drug, and Cosmetic A	1088	included as part of the [qualified medical provider's] recommending medical
1091the patient, by a provider who is:1092(A) a licensed board-eligible or board-certified psychiatrist;1093(B) a licensed psychologist with a master's-level degree;1094(C) a licensed clinical social worker with a master's-level degree;1095(D) a licensed advanced practice registered nurse who is qualified to practice1096within the psychiatric mental health nursing specialty and who has completed1097the clinical practice requirements in psychiatric mental health nursing,1098including in psychotherapy, in accordance with Subsection 58-31b-302(5)(g);1099or1100(E) a licensed physician assistant who is qualified to specialize in mental health1101care under Section 58-70a-501.1;1102(k) autism;1103(I) a terminal illness when the patient's remaining life expectancy is less than six months;1104(m) a condition resulting in the individual receiving hospice care;1105(n) a rare condition or disease that:1106(i) affects less than 200,000 individuals in the United States, as defined in Section1107526 of the Federal Food, Drug, and Cosmetic Act; and1108(ii) is not adequately managed despite treatment attempts using:1110(B) physical interventions;1111(o) pain lasting longer than two weeks that is not adequately managed, in the [qualified112medical provider's] recommending medical provider's opinion, despite treatment113attempts using:114(i) conventional medications other than opioids or opiates; or1118<	1089	provider's pre-treatment assessment and medical record documentation; or
1092(A) a licensed board-eligible or board-certified psychiatrist;1093(B) a licensed psychologist with a master's-level degree;1094(C) a licensed clinical social worker with a master's-level degree;1095(D) a licensed advanced practice registered nurse who is qualified to practice1096within the psychiatric mental health nursing specialty and who has completed1097the clinical practice requirements in psychiatric mental health nursing,1098including in psychotherapy, in accordance with Subsection 58-31b-302(5)(g);1099or1100(E) a licensed physician assistant who is qualified to specialize in mental health1101care under Section 58-70a-501.1;1102(k) autism;1103(I) a terminal illness when the patient's remaining life expectancy is less than six months;1104(m) a condition resulting in the individual receiving hospice care;1105(n) a rare condition or disease that:1106(i) affects less than 200,000 individuals in the United States, as defined in Section1107526 of the Federal Food, Drug, and Cosmetic Act; and1108(ii) is not adequately managed despite treatment attempts using:1109(A) conventional medications other than opioids or opiates; or1110(b) physical interventions;1111(o) pain lasting longer than two weeks that is not adequately managed, in the [qualified1112medical provider's) recommending medical provider's opinion, despite treatment1113attempts using:1114(i) conventional medications other than opioids or opi	1090	(ii) has been diagnosed or confirmed, through face-to-face or telehealth evaluation of
1093(B) a licensed psychologist with a master's-level degree;1094(C) a licensed clinical social worker with a master's-level degree;1095(D) a licensed advanced practice registered nurse who is qualified to practice1096within the psychiatric mental health nursing specialty and who has completed1097the clinical practice requirements in psychiatric mental health nursing,1098including in psychotherapy, in accordance with Subsection 58-31b-302(5)(g);1099or1100(E) a licensed physician assistant who is qualified to specialize in mental health1101care under Section 58-70a-501.1;1102(k) autism;1103(I) a terminal illness when the patient's remaining life expectancy is less than six months;1104(m) a condition resulting in the individual receiving hospice care;1105(n) a rare condition or disease that:1106(i) affects less than 200,000 individuals in the United States, as defined in Section1107526 of the Federal Food, Drug, and Cosmetic Act; and1108(ii) is not adequately managed despite treatment attempts using:1109(A) conventional medications other than opioids or opiates; or1111(o) pain lasting longer than two weeks that is not adequately managed, in the [qualified1113attempts using:1114(i) conventional medications other than opioids or opiates; or1115(ii) physical interventions;1116(p) pain that is expected to last for two weeks or longer for an acute condition, including1117a surgical procedure, for which a medica	1091	the patient, by a provider who is:
1094(C) a licensed clinical social worker with a master's-level degree;1095(D) a licensed advanced practice registered nurse who is qualified to practice1096within the psychiatric mental health nursing specialty and who has completed1097the clinical practice requirements in psychiatric mental health nursing,1098including in psychotherapy, in accordance with Subsection 58-31b-302(5)(g);1099or1100(E) a licensed physician assistant who is qualified to specialize in mental health1101care under Section 58-70a-501.1;1102(k) autism;1103(I) a terminal illness when the patient's remaining life expectancy is less than six months;1104(m) a condition resulting in the individual receiving hospice care;1105(n) a rare condition or disease that:1106(i) affects less than 200,000 individuals in the United States, as defined in Section1107526 of the Federal Food, Drug, and Cosmetic Act; and1108(ii) is not adequately managed despite treatment attempts using:1109(A) conventional medications other than opioids or opiates; or1110(b) physical interventions;1111(o) pain lasting longer than two weeks that is not adequately managed, in the [qualified1113attempts using:1114(i) conventional medications other than opioids or opiates; or1115(ii) physical interventions;1114(i) conventional medications other than opioids or opiates; or1115(ii) physical interventions;1116(p) pain that is expected to last for tw	1092	(A) a licensed board-eligible or board-certified psychiatrist;
1095(D) a licensed advanced practice registered nurse who is qualified to practice1096within the psychiatric mental health nursing specialty and who has completed1097the clinical practice requirements in psychiatric mental health nursing,1098including in psychotherapy, in accordance with Subsection 58-31b-302(5)(g);1099or1100(E) a licensed physician assistant who is qualified to specialize in mental health1101care under Section 58-70a-501.1;1102(k) autism;1103(l) a terminal illness when the patient's remaining life expectancy is less than six months;1104(m) a condition resulting in the individual receiving hospice care;1105(n) a rare condition or disease that:1106(i) affects less than 200,000 individuals in the United States, as defined in Section1107526 of the Federal Food, Drug, and Cosmetic Act; and1108(ii) is not adequately managed despite treatment attempts using:1109(A) conventional medications other than opioids or opiates; or1111(o) pain lasting longer than two weeks that is not adequately managed, in the [qualified1113attempts using:1114(i) conventional medications other than opioids or opiates; or1115(ii) physical interventions;1116(p) pain that is expected to last for two weeks or longer for an acute condition, including1117a surgical procedure, for which a medical professional may generally prescribe	1093	(B) a licensed psychologist with a master's-level degree;
1096within the psychiatric mental health nursing specialty and who has completed1097the clinical practice requirements in psychiatric mental health nursing,1098including in psychotherapy, in accordance with Subsection 58-31b-302(5)(g);1099or1100(E) a licensed physician assistant who is qualified to specialize in mental health1101care under Section 58-70a-501.1;1102(k) autism;1103(l) a terminal illness when the patient's remaining life expectancy is less than six months;1104(m) a condition resulting in the individual receiving hospice care;1105(n) a rare condition or disease that:1106(i) affects less than 200,000 individuals in the United States, as defined in Section1107526 of the Federal Food, Drug, and Cosmetic Act; and1108(ii) is not adequately managed despite treatment attempts using:1109(A) conventional medications other than opioids or opiates; or1111(o) pain lasting longer than two weeks that is not adequately managed, in the [qualified1112medical provider's] recommending medical provider's opinion, despite treatment1113attempts using:1114(i) conventional medications other than opioids or opiates; or1115(ii) physical interventions;1116(p) pain that is expected to last for two weeks or longer for an acute condition, including1117a surgical procedure, for which a medical professional may generally prescribe	1094	(C) a licensed clinical social worker with a master's-level degree;
1097the clinical practice requirements in psychiatric mental health nursing,1098including in psychotherapy, in accordance with Subsection 58-31b-302(5)(g);1099or1100(E) a licensed physician assistant who is qualified to specialize in mental health1101care under Section 58-70a-501.1;1102(k) autism;1103(l) a terminal illness when the patient's remaining life expectancy is less than six months;1104(m) a condition resulting in the individual receiving hospice care;1105(n) a rare condition or disease that:1106(i) affects less than 200,000 individuals in the United States, as defined in Section1107526 of the Federal Food, Drug, and Cosmetic Act; and1108(ii) is not adequately managed despite treatment attempts using:1109(A) conventional medications other than opioids or opiates; or1111(o) pain lasting longer than two weeks that is not adequately managed, in the [qualified1112medical provider's] recommending medical provider's opinion, despite treatment1113attempts using:1114(i) conventional medications other than opioids or opiates; or1115(ii) physical interventions;1116(p) pain that is expected to last for two weeks or longer for an acute condition, including1117a surgical procedure, for which a medical professional may generally prescribe	1095	(D) a licensed advanced practice registered nurse who is qualified to practice
1098including in psychotherapy, in accordance with Subsection 58-31b-302(5)(g);1099or1100(E) a licensed physician assistant who is qualified to specialize in mental health1101care under Section 58-70a-501.1;1102(k) autism;1103(l) a terminal illness when the patient's remaining life expectancy is less than six months;1104(m) a condition resulting in the individual receiving hospice care;1105(n) a rare condition or disease that:1106(i) affects less than 200,000 individuals in the United States, as defined in Section1107526 of the Federal Food, Drug, and Cosmetic Act; and1108(ii) is not adequately managed despite treatment attempts using:1109(A) conventional medications other than opioids or opiates; or1110(B) physical interventions;1111(o) pain lasting longer than two weeks that is not adequately managed, in the [qualified1112medical provider's] recommending medical provider's opinion, despite treatment1113attempts using:1114(i) conventional medications other than opioids or opiates; or1115(ii) physical interventions;1116(p) pain that is expected to last for two weeks or longer for an acute condition, including1117a surgical procedure, for which a medical professional may generally prescribe	1096	within the psychiatric mental health nursing specialty and who has completed
1099or1100(E) a licensed physician assistant who is qualified to specialize in mental health1101care under Section 58-70a-501.1;1102(k) autism;1103(l) a terminal illness when the patient's remaining life expectancy is less than six months;1104(m) a condition resulting in the individual receiving hospice care;1105(n) a rare condition or disease that:1106(i) affects less than 200,000 individuals in the United States, as defined in Section1107526 of the Federal Food, Drug, and Cosmetic Act; and1108(ii) is not adequately managed despite treatment attempts using:1109(A) conventional medications other than opioids or opiates; or1111(o) pain lasting longer than two weeks that is not adequately managed, in the [qualified1112medical provider's] recommending medical provider's opinion, despite treatment1113attempts using:1114(i) conventional medications other than opioids or opiates; or1115(ii) physical interventions;1114(i) conventional medications other than opioids or opiates; or1113attempts using:1114(i) conventional medications other than opioids or opiates; or1115(ii) physical interventions;1116(p) pain that is expected to last for two weeks or longer for an acute condition, including1117a surgical procedure, for which a medical professional may generally prescribe	1097	the clinical practice requirements in psychiatric mental health nursing,
1100(E) a licensed physician assistant who is qualified to specialize in mental health1101care under Section 58-70a-501.1;1102(k) autism;1103(l) a terminal illness when the patient's remaining life expectancy is less than six months;1104(m) a condition resulting in the individual receiving hospice care;1105(n) a rare condition or disease that:1106(i) affects less than 200,000 individuals in the United States, as defined in Section1107526 of the Federal Food, Drug, and Cosmetic Act; and1108(ii) is not adequately managed despite treatment attempts using:1109(A) conventional medications other than opioids or opiates; or1111(o) pain lasting longer than two weeks that is not adequately managed, in the [qualified1113attempts using:1114(i) conventional medications other than opioids or opiates; or1113attempts using:1114(i) conventional medications other than opioids or opiates; or1113attempts using:1114(i) conventional medications other than opioids or opiates; or1115(ii) physical interventions;1116(p) pain that is expected to last for two weeks or longer for an acute condition, including1117a surgical procedure, for which a medical professional may generally prescribe	1098	including in psychotherapy, in accordance with Subsection 58-31b-302(5)(g);
1101care under Section 58-70a-501.1;1102(k) autism;1103(l) a terminal illness when the patient's remaining life expectancy is less than six months;1104(m) a condition resulting in the individual receiving hospice care;1105(n) a rare condition or disease that:1106(i) affects less than 200,000 individuals in the United States, as defined in Section1107526 of the Federal Food, Drug, and Cosmetic Act; and1108(ii) is not adequately managed despite treatment attempts using:1109(A) conventional medications other than opioids or opiates; or1110(B) physical interventions;1111(o) pain lasting longer than two weeks that is not adequately managed, in the [qualified1112medical provider's] recommending medical provider's opinion, despite treatment1113attempts using:1114(i) conventional medications other than opioids or opiates; or1113medical provider's] recommending medical provider's opinion, despite treatment1113attempts using:1114(i) conventional medications other than opioids or opiates; or1115(ii) physical interventions;1116(p) pain that is expected to last for two weeks or longer for an acute condition, including1117a surgical procedure, for which a medical professional may generally prescribe	1099	or
1102(k) autism;1103(l) a terminal illness when the patient's remaining life expectancy is less than six months;1104(m) a condition resulting in the individual receiving hospice care;1105(n) a rare condition or disease that:1106(i) affects less than 200,000 individuals in the United States, as defined in Section1107526 of the Federal Food, Drug, and Cosmetic Act; and1108(ii) is not adequately managed despite treatment attempts using:1109(A) conventional medications other than opioids or opiates; or1110(B) physical interventions;1111(o) pain lasting longer than two weeks that is not adequately managed, in the [qualified1112medical provider's] recommending medical provider's opinion, despite treatment1113attempts using:1114(i) conventional medications other than opioids or opiates; or1113attempts using:1114(j) pain that is expected to last for two weeks or longer for an acute condition, including1117a surgical procedure, for which a medical professional may generally prescribe	1100	(E) a licensed physician assistant who is qualified to specialize in mental health
1103(1) a terminal illness when the patient's remaining life expectancy is less than six months;1104(m) a condition resulting in the individual receiving hospice care;1105(n) a rare condition or disease that:1106(i) affects less than 200,000 individuals in the United States, as defined in Section1107526 of the Federal Food, Drug, and Cosmetic Act; and1108(ii) is not adequately managed despite treatment attempts using:1109(A) conventional medications other than opioids or opiates; or1110(B) physical interventions;1111(o) pain lasting longer than two weeks that is not adequately managed, in the [qualified1112medical provider's] recommending medical provider's opinion, despite treatment1113attempts using:1114(i) conventional medications other than opioids or opiates; or1115(ii) physical interventions;1114(j) pain that is expected to last for two weeks or longer for an acute condition, including1117a surgical procedure, for which a medical professional may generally prescribe	1101	care under Section 58-70a-501.1;
1104(m) a condition resulting in the individual receiving hospice care;1105(n) a rare condition or disease that:1106(i) affects less than 200,000 individuals in the United States, as defined in Section1107526 of the Federal Food, Drug, and Cosmetic Act; and1108(ii) is not adequately managed despite treatment attempts using:1109(A) conventional medications other than opioids or opiates; or1110(B) physical interventions;1111(o) pain lasting longer than two weeks that is not adequately managed, in the [qualified1112medical provider's] recommending medical provider's opinion, despite treatment1113attempts using:1114(i) conventional medications other than opioids or opiates; or1115(ii) physical interventions;1114(i) conventional medications other than opioids or opiates; or1115(ii) physical interventions;1114(i) conventional medications other than opioids or opiates; or1115(ii) physical interventions;1116(p) pain that is expected to last for two weeks or longer for an acute condition, including1117a surgical procedure, for which a medical professional may generally prescribe	1102	(k) autism;
1105(n) a rare condition or disease that:1106(i) affects less than 200,000 individuals in the United States, as defined in Section1107526 of the Federal Food, Drug, and Cosmetic Act; and1108(ii) is not adequately managed despite treatment attempts using:1109(A) conventional medications other than opioids or opiates; or1110(B) physical interventions;1111(o) pain lasting longer than two weeks that is not adequately managed, in the [qualified1112medical provider's] recommending medical provider's opinion, despite treatment1113attempts using:1114(i) conventional medications other than opioids or opiates; or1115(ii) physical interventions;1116(p) pain that is expected to last for two weeks or longer for an acute condition, including1117a surgical procedure, for which a medical professional may generally prescribe	1103	(1) a terminal illness when the patient's remaining life expectancy is less than six months;
<ul> <li>(i) affects less than 200,000 individuals in the United States, as defined in Section</li> <li>526 of the Federal Food, Drug, and Cosmetic Act; and</li> <li>(ii) is not adequately managed despite treatment attempts using:</li> <li>(A) conventional medications other than opioids or opiates; or</li> <li>(B) physical interventions;</li> <li>(o) pain lasting longer than two weeks that is not adequately managed, in the [qualified</li> <li>medical provider's] recommending medical provider's opinion, despite treatment</li> <li>(i) conventional medications other than opioids or opiates; or</li> <li>(ii) is not adequately managed despite treatment attempts using:</li> <li>(i) conventional medications other than opioids or opiates; or</li> <li>(ii) physical interventions;</li> <li>(j) point that is expected to last for two weeks or longer for an acute condition, including a surgical procedure, for which a medical professional may generally prescribe</li> </ul>	1104	(m) a condition resulting in the individual receiving hospice care;
1107526 of the Federal Food, Drug, and Cosmetic Act; and1108(ii) is not adequately managed despite treatment attempts using:1109(A) conventional medications other than opioids or opiates; or1110(B) physical interventions;1111(o) pain lasting longer than two weeks that is not adequately managed, in the [qualified1112medical provider's] recommending medical provider's opinion, despite treatment1113attempts using:1114(i) conventional medications other than opioids or opiates; or1115(ii) physical interventions;1116(p) pain that is expected to last for two weeks or longer for an acute condition, including a surgical procedure, for which a medical professional may generally prescribe	1105	(n) a rare condition or disease that:
<ul> <li>(ii) is not adequately managed despite treatment attempts using:</li> <li>(A) conventional medications other than opioids or opiates; or</li> <li>(B) physical interventions;</li> <li>(o) pain lasting longer than two weeks that is not adequately managed, in the [qualified medical provider's] recommending medical provider's opinion, despite treatment attempts using:</li> <li>(i) conventional medications other than opioids or opiates; or</li> <li>(ii) conventional medications other than opioids or opiates; or</li> <li>(ii) physical interventions;</li> <li>(j) pain that is expected to last for two weeks or longer for an acute condition, including a surgical procedure, for which a medical professional may generally prescribe</li> </ul>	1106	
<ul> <li>(A) conventional medications other than opioids or opiates; or</li> <li>(B) physical interventions;</li> <li>(o) pain lasting longer than two weeks that is not adequately managed, in the [qualified medical provider's] recommending medical provider's opinion, despite treatment attempts using:</li> <li>(i) conventional medications other than opioids or opiates; or</li> <li>(ii) conventional medications other than opioids or opiates; or</li> <li>(j) pain that is expected to last for two weeks or longer for an acute condition, including a surgical procedure, for which a medical professional may generally prescribe</li> </ul>	1107	526 of the Federal Food, Drug, and Cosmetic Act; and
<ul> <li>(B) physical interventions;</li> <li>(o) pain lasting longer than two weeks that is not adequately managed, in the [qualified medical provider's] recommending medical provider's opinion, despite treatment attempts using:</li> <li>(i) conventional medications other than opioids or opiates; or</li> <li>(ii) physical interventions;</li> <li>(p) pain that is expected to last for two weeks or longer for an acute condition, including a surgical procedure, for which a medical professional may generally prescribe</li> </ul>	1108	(ii) is not adequately managed despite treatment attempts using:
<ul> <li>(o) pain lasting longer than two weeks that is not adequately managed, in the [qualified medical provider's] recommending medical provider's opinion, despite treatment attempts using:</li> <li>(i) conventional medications other than opioids or opiates; or</li> <li>(ii) physical interventions;</li> <li>(p) pain that is expected to last for two weeks or longer for an acute condition, including a surgical procedure, for which a medical professional may generally prescribe</li> </ul>		
1112medical provider's] recommending medical provider's opinion, despite treatment1113attempts using:1114(i) conventional medications other than opioids or opiates; or1115(ii) physical interventions;1116(p) pain that is expected to last for two weeks or longer for an acute condition, including1117a surgical procedure, for which a medical professional may generally prescribe		
1113attempts using:1114(i) conventional medications other than opioids or opiates; or1115(ii) physical interventions;1116(p) pain that is expected to last for two weeks or longer for an acute condition, including1117a surgical procedure, for which a medical professional may generally prescribe		
<ul> <li>(i) conventional medications other than opioids or opiates; or</li> <li>(ii) physical interventions;</li> <li>(p) pain that is expected to last for two weeks or longer for an acute condition, including</li> <li>a surgical procedure, for which a medical professional may generally prescribe</li> </ul>		
<ul> <li>(ii) physical interventions;</li> <li>(p) pain that is expected to last for two weeks or longer for an acute condition, including</li> <li>a surgical procedure, for which a medical professional may generally prescribe</li> </ul>		
<ul> <li>(p) pain that is expected to last for two weeks or longer for an acute condition, including</li> <li>a surgical procedure, for which a medical professional may generally prescribe</li> </ul>		
a surgical procedure, for which a medical professional may generally prescribe		
opioids for a limited duration, subject to Subsection 26B-4-213(5)(c); and		
	1118	opioids for a limited duration, subject to Subsection 26B-4-213(5)(c); and

1119	(q) a condition that the Compassionate Use Board approves under Section 26B-1-421,
1120	on an individual, case-by-case basis.
1121	Section 9. Section <b>26B-4-204</b> is amended to read:
1122	26B-4-204 . Treatment recommendation.
1123	(1)(a)(i) [Except as provided in Subsection (1)(b), an individual may not recommend
1124	a medical cannabis treatment unless the department registers the individual as a
1125	qualified medical provider in accordance with this section.] A recommending
1126	medical provider may recommend medical cannabis.
1127	(ii) Notwithstanding Subsection (1)(a)(i), a [qualified medical provider]
1128	recommending medical provider who is podiatrist licensed under Title 58, Chapter
1129	5a, Podiatric Physician Licensing Act, may not recommend a medical cannabis
1130	treatment except within the course and scope of a practice of podiatry, as that term
1131	is defined in Section 58-5a-102.
1132	[(b) An individual who meets the recommending qualifications may recommend a
1133	medical cannabis treatment as a limited medical provider without registering under
1134	Subsection (1)(a) if:]
1135	[(i) the individual recommends the use of medical cannabis to the patient through an
1136	order described in Subsection (1)(c) after:]
1137	[(A) a face-to-face visit for an initial recommendation or the renewal of a
1138	recommendation for a patient for whom the limited medical provider did not
1139	make the patient's original recommendation; or]
1140	[(B) a visit using telehealth services for a renewal of a recommendation for a
1141	patient for whom the limited medical provider made the patient's original
1142	recommendation; and]
1143	[(ii) the individual's recommendation or renewal would not cause the total number of
1144	the individual's patients who have a valid medical cannabis patient card or
1145	provisional patient card resulting from the individual's recommendation to exceed
1146	<del>15.</del> ]
1147	[(c)] (b) [The individual described in Subsection (1)(b) shall ] A recommending medical
1148	provider may communicate the individual's recommendation through an order for the
1149	medical cannabis pharmacy to record the individual's recommendation or renewal in
1150	the state electronic verification system under the individual's recommendation that:
1151	(i)(A) the individual or the individual's employee sends electronically to a medical
1152	cannabis pharmacy; or

1150	
1153	(B) the individual gives to the patient in writing for the patient to deliver to a
1154	medical cannabis pharmacy; and
1155	(ii) may include:
1156	(A) directions of use or dosing guidelines; and
1157	(B) an indication of a need for a caregiver in accordance with Subsection
1158	26B-4-213(3)(c).
1159	[(d)] (c) If the [limited medical provider] recommending medical provider gives the
1160	patient a written recommendation to deliver to a medical cannabis pharmacy under
1161	Subsection [(1)(c)(i)(B), the limited medical provider] (1)(b)(i)(B), the recommending
1162	medical provider shall ensure that the document includes all of the information that is
1163	included on a prescription the provider would issue for a controlled substance,
1164	including:
1165	(i) the date of issuance;
1166	(ii) the provider's name, address and contact information, controlled substance license
1167	information, and signature; and
1168	(iii) the patient's name, address and contact information, age, and diagnosed
1169	qualifying condition.
1170	[(e)] (d) In considering making a recommendation as a [limited medical provider]
1171	recommending medical provider, an individual may consult information that the
1172	department makes available on the department's website for recommending providers.
1173	[(2)(a) The department shall, within 15 days after the day on which the department
1174	receives an application from an individual, register and issue a qualified medical
1175	provider registration card to the individual if the individual:]
1176	[(i) provides to the department the individual's name and address;]
1177	[(ii) provides to the department an acknowledgment that the individual has completed
1178	four hours of continuing education related to medical cannabis;]
1179	[(iii) provides to the department evidence that the individual meets the
1180	recommending qualifications;]
1181	[(iv) for an applicant on or after November 1, 2021, provides to the department the
1182	information described in Subsection (10)(a); and]
1183	[(v) pays the department a fee in an amount that:]
1184	[(A) the department sets, in accordance with Section 63J-1-504; and]
1185	[(B) does not exceed \$300 for an initial registration.]
1186	[(b) The department may not register an individual as a qualified medical provider if the

1187	individual is:]
1188	[(i) a pharmacy medical provider; or]
1189	[(ii) an owner, officer, director, board member, employee, or agent of a cannabis
1190	production establishment, a medical cannabis pharmacy, or a medical cannabis
1191	courier.]
1192	[(3)] (2)[(a) An individual shall complete the continuing education related to medical
1193	cannabis in the following amounts:]
1194	[(i) for an individual as a condition precedent to registration, four hours; and]
1195	[(ii) for a qualified medical provider as a condition precedent to renewal, four hours
1196	every two years.]
1197	[(b)] (a) The department may, in consultation with the Division of Professional
1198	Licensing, develop continuing education related to medical cannabis.
1199	[(e)] (b) The continuing education described in this Subsection $[(3)]$ (2) may discuss:
1200	(i) the provisions of this part;
1201	(ii) general information about medical cannabis under federal and state law;
1202	(iii) the latest scientific research on the endocannabinoid system and medical
1203	cannabis, including risks and benefits;
1204	(iv) recommendations for medical cannabis as it relates to the continuing care of a
1205	patient in pain management, risk management, potential addiction, or palliative
1206	care; and
1207	(v) best practices for recommending the form and dosage of medical cannabis based
1208	on the qualifying condition underlying a medical cannabis recommendation.
1209	[(4)] (3)(a) Except as provided in Subsection [(4)(b)] (3)(b), a [qualified medical provider]
1210	recommending medical provider may not recommend a medical cannabis treatment
1211	to more than 1.5% of the total amount of medical cannabis patient cardholders.
1212	(b) If a [qualified medical provider] recommending medical provider receives payment
1213	from an insurance plan for services provided under this chapter, then the patient
1214	whose insurance plan was billed does not count toward the 1.5% patient cap
1215	described in Subsection [ $(4)(a)$ ] (3)(a).
1216	[(5)] (4) A recommending medical provider may recommend medical cannabis to an
1217	individual under this part only in the course of a provider-patient relationship after the
1218	recommending medical provider has completed and documented in the patient's medical
1219	record a thorough assessment of the patient's condition and medical history based on the
1220	appropriate standard of care for the patient's condition.

1221	[(6)(a) Except as provided in Subsections (6)(b) and (c), a person may not advertise that
1222	the person or the person's employee recommends a medical cannabis treatment.]
1223	[(b) Notwithstanding Subsection (6)(a) and Section 4-41a-109, a qualified medical
1224	provider, medical clinic, or medical office that employs a qualified medical provider
1225	may advertise only the following:]
1226	[(i) a green cross;]
1227	[(ii) the provider's or clinic's name and logo;]
1228	[(iii) a qualifying condition that the individual treats;]
1229	[(iv) that the qualified medical provider, medical clinic, or medical office evaluates
1230	patients for medical cannabis recommendations;]
1231	[(v) a scientific study regarding medical cannabis use; or]
1232	[(vi) contact information.]
1233	[(c) Notwithstanding Subsection (6)(a) and Section 4-41a-109, qualified medical
1234	provider, medical clinic, or medical office that employs a qualified medical provider
1235	may engage in targeted marketing, as determined by the department through rule, for
1236	advertising medical cannabis recommendation services.]
1237	[(7)(a) A qualified medical provider registration card expires two years after the day on
1238	which the department issues the card.]
1239	[(b) The department shall renew a qualified medical provider's registration card if the
1240	provider:]
1241	[(i) applies for renewal;]
1242	[(ii) is eligible for a qualified medical provider registration card under this section,
1243	including maintaining an unrestricted license under the recommending
1244	qualifications;]
1245	[(iii) certifies to the department in a renewal application that the information in
1246	Subsection (2)(a) is accurate or updates the information;]
1247	[(iv) submits a report detailing the completion of the continuing education
1248	requirement described in Subsection (3); and]
1249	[(v) pays the department a fee in an amount that:]
1250	[(A) the department sets, in accordance with Section 63J-1-504; and]
1251	[(B) does not exceed \$50 for a registration renewal.]
1252	[(8) The department may revoke the registration of a qualified medical provider who fails
1253	to maintain compliance with the requirements of this section.]
1254	[(9) A recommending medical provider may not:]

1255	[(a) receive any compensation or benefit for the qualified medical provider's medical
1256	cannabis treatment recommendation from:]
1257	[(i) a cannabis production establishment or an owner, officer, director, board
1258	member, employee, or agent of a cannabis production establishment;]
1259	[(ii) a medical cannabis pharmacy or an owner, officer, director, board member,
1260	employee, or agent of a medical cannabis pharmacy; or]
1261	[(iii) a recommending medical provider or pharmacy medical provider; or]
1262	[(b) provide a medical cannabis recommendation at a medical clinic or medical office
1263	that is violating the advertising limitations described in Subsection (6).]
1264	[(10)] (5)(a) [Each quarter, a qualified medical provider shall report to the department, in
1265	a manner designated by the department:] The department shall host a recommending
1266	provider contact list on the department's website that contains the information
1267	described in Subsection (5)(b).
1268	[(i) if applicable, that the qualified medical provider or the entity that employs the
1269	qualified medical provider represents online or on printed material that the
1270	qualified medical provider is a qualified medical provider or offers medical
1271	cannabis recommendations to patients; and]
1272	[(ii)(A) for cash payment without insurance, the fee amount that the qualified
1273	medical provider or the entity that employs the qualified medical provider
1274	charges a patient for a medical cannabis recommendation as an actual cash
1275	rate; and]
1276	[(B) whether the qualified medical provider or the entity that employs the
1277	qualified medical provider bills insurance.]
1278	(b) [The department shall:] A recommending medical provider that elects to be included
1279	on the contact list shall provide the department the following:
1280	[(i) ensure that the following information related to qualified medical providers and
1281	entities described in Subsection (10)(a)(i) is available on the department's website
1282	or on the health care price transparency tool under Subsection (10)(b)(ii):]
1283	[(A)] (i) the name of the [qualified medical provider] recommending medical provider
1284	and, if applicable, the name of the entity that employs the [qualified medical
1285	provider] recommending medical provider;
1286	[(B)] (ii) the address of the [qualified medical provider's] recommending medical
1287	provider's office or, if applicable, the entity that employs the [qualified medical
1288	provider] recommending medical provider; and

1289	[(C)] (iii)(A) the fee amount [described in Subsection (10)(a)(ii)(A); and] charged
1290	by the qualified medical provider; or
1291	(B) whether the recommending medical provider or entity that employs the
1292	recommending medical provider bills insurance.
1293	[(ii)] (c) <u>The department shall</u> share data collected under this Subsection [(10)] (5) with
1294	the state auditor for use in the health care price transparency tool[-described in
1295	Section 67-3-11].
1296	Section 10. Section <b>26B-4-205</b> is amended to read:
1297	26B-4-205 . Standard of care Physicians and pharmacists not liable No
1298	private right of action.
1299	(1) An individual described in Subsection (2) is not subject to the following solely for
1300	violating a federal law or regulation that would otherwise prohibit recommending,
1301	prescribing, or dispensing medical cannabis, a medical cannabis product, or a
1302	cannabis-based drug that the United States Food and Drug Administration has not
1303	approved:
1304	(a) civil or criminal liability; or
1305	(b) licensure sanctions under Title 58, Chapter 17b, Pharmacy Practice Act, Title 58,
1306	Chapter 31b, Nurse Practice Act, Title 58, Chapter 67, Utah Medical Practice Act,
1307	Title 58, Chapter 68, Utah Osteopathic Medical Practice Act, or Title 58, Chapter
1308	70a, Utah Physician Assistant Act.
1309	(2) The limitations of liability described in Subsection (1) apply to:
1310	[(a) a podiatrist licensed under Title 58, Chapter 5a, Podiatric Physician Licensing Act,
1311	an advanced practice registered nurse licensed under Title 58, Chapter 31b, Nurse
1312	Practice Act, a physician licensed under Title 58, Chapter 67, Utah Medical Practice
1313	Act, or Title 58, Chapter 68, Utah Osteopathic Medical Practice Act, or a physician
1314	assistant licensed under Title 58, Chapter 70a, Utah Physician Assistant Act:]
1315	[(i)(A) whom the department has registered as a qualified medical provider; or]
1316	[(B) who makes a recommendation as a limited medical provider; and]
1317	[(ii)] (a) a recommending medical provider who recommends treatment with cannabis in
1318	a medicinal dosage form or a cannabis product in a medicinal dosage form to a
1319	patient in accordance with this part; and
1320	(b) a pharmacist licensed under Title 58, Chapter 17b, Pharmacy Practice Act:
1321	(i) whom the department has registered as a pharmacy medical provider; and
1322	(ii) who dispenses, in a medical cannabis pharmacy, treatment with cannabis in a

1323	medicinal dosage form or a cannabis product in a medicinal dosage form to a
1324	medical cannabis cardholder in accordance with this part.
1325	(3) Nothing in this section or part reduces or in any way negates the duty of an individual
1326	described in Subsection (2) to use reasonable and ordinary care in the treatment of a
1327	patient:
1328	(a) who may have a qualifying condition; and
1329	(b)(i) for whom the individual described in Subsection [ $(2)(a)(i)$ or (ii) ] (2)(a) has
1330	recommended or might consider recommending a treatment with cannabis or a
1331	cannabis product; or
1332	(ii) with whom the pharmacist described in Subsection (2)(b) has interacted in the
1333	dosing or dispensing of cannabis or a cannabis product.
1334	(4)(a) As used in this Subsection (4), "healthcare facility" means a health care facility as
1335	defined in Section 26B-2-201.
1336	(b) A healthcare facility may adopt restrictions on the possession, use, and storage of
1337	medical cannabis on the premises of the healthcare facility by a medical cannabis
1338	cardholder who resides at or is actively receiving treatment or care at the healthcare
1339	facility.
1340	(c) An employee or agent of a healthcare facility described in this Subsection (4) is not
1341	subject to civil or criminal liability for carrying out employment duties, including:
1342	(i) providing or supervising care to a medical cannabis cardholder; or
1343	(ii) in accordance with a caregiver designation under Section 26B-4-214 for a
1344	medical cannabis cardholder residing at the healthcare facility, purchasing,
1345	transporting, or possessing medical cannabis for the relevant patient and in
1346	accordance with the designation.
1347	(d) Nothing in this section requires a healthcare facility to adopt a restriction under
1348	Subsection (4)(b).
1349	Section 11. Section 26B-4-213 is amended to read:
1350	26B-4-213 . Medical cannabis patient card Medical cannabis guardian card
1351	Conditional medical cannabis card Application Fees Studies.
1352	(1)(a) Subject to Section 26B-4-246, within 15 days after the day on which an individual
1353	who satisfies the eligibility criteria in this section or Section 26B-4-214 submits an
1354	application in accordance with this section or Section 26B-4-214, the department
1355	shall:
1356	(i) issue a medical cannabis patient card to an individual described in Subsection

1357	(2)(a);
1358	(ii) issue a medical cannabis guardian card to an individual described in Subsection
1359	(1) issue a medical calmaons guardian care to an marviadal described in Subsection (2)(b);
1360	(iii) issue a provisional patient card to a minor described in Subsection (2)(c); and
1361	(iv) issue a medical cannabis caregiver card to an individual described in Subsection
1362	26B-4-214(4).
1363	(b)(i) Upon the entry of a recommending medical provider's medical cannabis
1364	recommendation for a patient in the state electronic verification system, either by
1365	the provider or the provider's employee or by a medical cannabis pharmacy
1366	medical provider or medical cannabis pharmacy in accordance with Subsection
1367	4-41a-1101(10)(a), the department shall issue to the patient an electronic
1368	conditional medical cannabis card, in accordance with this Subsection (1)(b).
1369	(ii) A conditional medical cannabis card is valid for the lesser of:
1370	(A) 60 days; or
1371	(B) the day on which the department completes the department's review and issues
1372	a medical cannabis card under Subsection (1)(a), denies the patient's medical
1373	cannabis card application, or revokes the conditional medical cannabis card
1374	under Subsection (8).
1375	(iii) The department may issue a conditional medical cannabis card to an individual
1376	applying for a medical cannabis patient card for which approval of the
1377	Compassionate Use Board is not required.
1378	(iv) An individual described in Subsection (1)(b)(iii) has the rights, restrictions, and
1379	obligations under law applicable to a holder of the medical cannabis card for
1380	which the individual applies and for which the department issues the conditional
1381	medical cannabis card.
1382	(2)(a) An individual is eligible for a medical cannabis patient card if:
1383	(i)(A) the individual is at least 21 years old; or
1384	(B) the individual is 18, 19, or 20 years old, the individual petitions the
1385	Compassionate Use Board under Section 26B-1-421, and the Compassionate
1386	Use Board recommends department approval of the petition;
1387	(ii) the individual is a Utah resident;
1388	(iii) the individual's recommending medical provider recommends treatment with
1389	medical cannabis in accordance with Subsection (4);
1390	(iv) the individual signs an acknowledgment stating that the individual received the

1391	information described in Subsection (9); and
1392	(v) the individual pays to the department a fee in an amount that, subject to
1393	Subsection 26B-1-310(5), the department sets in accordance with Section
1394	63J-1-504.
1395	(b)(i) An individual is eligible for a medical cannabis guardian card if the individual:
1396	(A) is at least 18 years old;
1397	(B) is a Utah resident;
1398	(C) is the parent or legal guardian of a minor for whom the minor's recommending
1399	medical provider recommends a medical cannabis treatment, the individual
1400	petitions the Compassionate Use Board under Section 26B-1-421, and the
1401	Compassionate Use Board recommends department approval of the petition;
1402	(D) the individual signs an acknowledgment stating that the individual received
1403	the information described in Subsection (9); and
1404	(E) pays to the department a fee in an amount that, subject to Subsection
1405	26B-1-310(5), the department sets in accordance with Section 63J-1-504, plus
1406	the cost of the criminal background check described in Section 26B-4-215.
1407	(ii) The department shall notify the Department of Public Safety of each individual
1408	that the department registers for a medical cannabis guardian card.
1409	(c)(i) A minor is eligible for a provisional patient card if:
1410	(A) the minor has a qualifying condition;
1411	(B) the minor's recommending medical provider recommends a medical cannabis
1412	treatment to address the minor's qualifying condition;
1413	(C) one of the minor's parents or legal guardians petitions the Compassionate Use
1414	Board under Section 26B-1-421, and the Compassionate Use Board
1415	recommends department approval of the petition; and
1416	(D) the minor's parent or legal guardian is eligible for a medical cannabis guardian
1417	card under Subsection (2)(b) or designates a caregiver under Subsection (2)(d)
1418	who is eligible for a medical cannabis caregiver card under Section 26B-4-214.
1419	(ii) The department shall automatically issue a provisional patient card to the minor
1420	described in Subsection $(2)(c)(i)$ at the same time the department issues a medical
1421	cannabis guardian card to the minor's parent or legal guardian.
1422	(d) If the parent or legal guardian of a minor described in Subsections (2)(c)(i)(A)
1423	through (C) does not qualify for a medical cannabis guardian card under Subsection
1424	(2)(b), the parent or legal guardian may designate up to two caregivers in accordance

1425	with Subsection $26B-4-214(1)(c)$ to ensure that the minor has adequate and safe
1426	access to the recommended medical cannabis treatment.
1427	(3)(a) An individual who is eligible for a medical cannabis card described in Subsection
1427	(2)(a) or (b) shall submit an application for a medical cannabis card to the department:
1429	(i) through an electronic application connected to the state electronic verification
1429	system;
1431	(ii) with the recommending medical provider; and
1432	(iii) with information including:
1433	(A) the applicant's name, gender, age, and address;
1434	<ul><li>(A) the applicant's name, gender, age, and address,</li><li>(B) the number of the applicant's government issued photo identification;</li></ul>
1434	<ul><li>(C) for a medical cannabis guardian card, the name, gender, and age of the minor</li></ul>
1435	receiving a medical cannabis treatment under the cardholder's medical cannabis
1430	guardian card; and
1437	(D) for a provisional patient card, the name of the minor's parent or legal guardian
1438	who holds the associated medical cannabis guardian card.
1439	(b) The department shall ensure that a medical cannabis card the department issues
1440	(b) The department shall ensure that a medical calinable cald the department issues under this section contains the information described in Subsection (3)(a)(iii).
1441	(c)(i) If a recommending medical provider determines that, because of age, illness, or
1442	
1445	disability, a medical cannabis patient cardholder requires assistance in
1444	administering the medical cannabis treatment that the recommending medical provider recommends, the recommending medical provider may indicate the
1445 1446	
	cardholder's need in the state electronic verification system, either directly or[ <del>, for</del>
1447	a limited medical provider,] through the order described in Subsections [
1448	$\frac{26B-4-204(1)(c) \text{ and } (d)}{26B-4-204(1)(b) \text{ and } (c)}$
1449	(ii) If a recommending medical provider makes the indication described in Subsection $(2)(a)(b)$
1450	Subsection $(3)(c)(i)$ :
1451	(A) the department shall add a label to the relevant medical cannabis patient card
1452	indicating the cardholder's need for assistance;
1453 1454	(B) any adult who is 18 years old or older and who is physically present with the
1454 1455	cardholder at the time the cardholder needs to use the recommended medical
1455 1456	cannabis treatment may handle the medical cannabis treatment and any
1456	associated medical cannabis device as needed to assist the cardholder in
1457	administering the recommended medical cannabis treatment; and
1458	(C) an individual of any age who is physically present with the cardholder in the

1459	event of an emergency medical condition, as that term is defined in Section
1460	31A-1-301, may handle the medical cannabis treatment and any associated
1461	medical cannabis device as needed to assist the cardholder in administering the
1461	recommended medical cannabis treatment.
1463	(iii) A non-cardholding individual acting under Subsection (3)(c)(ii)(B) or (C) may
1464	not:
1465	<ul><li>(A) ingest or inhale medical cannabis;</li><li>(B) respects transport, or her discussional connection of the medical connection.</li></ul>
1466	(B) possess, transport, or handle medical cannabis or a medical cannabis device
1467	outside of the immediate area where the cardholder is present or with an intent
1468	other than to provide assistance to the cardholder; or
1469	(C) possess, transport, or handle medical cannabis or a medical cannabis device
1470	when the cardholder is not in the process of being dosed with medical cannabis.
1471	(4) To recommend a medical cannabis treatment to a patient or to renew a recommendation,
1472	a recommending medical provider shall:
1473	(a) visit with the patient face-to-face for an initial recommendation unless the patient:
1474	(i) prefers a virtual visit; and
1475	(ii)(A) is on hospice or has a terminal illness according to the patient's medical
1476	provider; or
1477	(B) is a resident of an assisted living facility, as defined in Section 26B-2-201, or
1478	a nursing care facility, as defined in Section 26B-2-201;
1479	(b) before recommending or renewing a recommendation for medical cannabis in a
1480	medicinal dosage form or a cannabis product in a medicinal dosage form:
1481	(i) verify the patient's and, for a minor patient, the minor patient's parent or legal
1482	guardian's government issued photo identification described in Subsection (3)(a);
1483	(ii) review any record related to the patient and, for a minor patient, the patient's
1484	parent or legal guardian [in:] accessible to the recommending medical provider
1485	including in the controlled substance database created in Section 58-37f-201; and
1486	[(A) for a qualified medical provider, the state electronic verification system; and]
1487	[(B) the controlled substance database created in Section 58-37f-201; and]
1488	(iii) consider the recommendation in light of the patient's qualifying condition,
1489	history of substance use or opioid use disorder, and history of medical cannabis
1490	and controlled substance use during a visit with the patient; and
1491	(c) state in the recommending medical provider's recommendation that the patient:
1492	(i) suffers from a qualifying condition, including the type of qualifying condition; and

1493	(ii) may benefit from treatment with cannabis in a medicinal dosage form or a
1494	cannabis product in a medicinal dosage form.
1495	(5)(a) Except as provided in Subsection (5)(b) or (c), a medical cannabis card that the
1496	department issues under this section is valid for the lesser of:
1497	(i) an amount of time that the recommending medical provider determines; or
1498	(ii) one year from the day the card is issued.
1499	(b)(i) A medical cannabis card that the department issues in relation to a terminal
1500	illness described in Section 26B-4-203 expires after one year.
1501	(ii) The recommending medical provider may revoke a recommendation that the
1502	provider made in relation to a terminal illness described in Section 26B-4-203 if
1503	the medical cannabis cardholder no longer has the terminal illness.
1504	(c) A medical cannabis card that the department issues in relation to acute pain as
1505	described in Section 26B-4-203 expires 30 days after the day on which the
1506	department first issues a conditional or full medical cannabis card.
1507	(6)(a) A medical cannabis patient card or a medical cannabis guardian card is renewable
1508	if:
1509	(i) at the time of renewal, the cardholder meets the requirements of Subsection (2)(a)
1510	or (b); or
1511	(ii) the cardholder received the medical cannabis card through the recommendation of
1512	the Compassionate Use Board under Section 26B-1-421.
1513	(b) The recommending medical provider who made the underlying recommendation for
1514	the card of a cardholder described in Subsection (6)(a) may renew the cardholder's
1515	card through phone or video conference with the cardholder, at the recommending
1516	medical provider's discretion.
1517	(c) Before having access to a renewed card, a cardholder under Subsection (2)(a) or (b)
1518	shall pay to the department a renewal fee in an amount that:
1519	(i) subject to Subsection 26B-1-310(5), the department sets in accordance with
1520	Section 63J-1-504; and
1521	(ii) may not exceed the cost of the relatively lower administrative burden of renewal
1522	in comparison to the original application process.
1523	(d) If a minor meets the requirements of Subsection (2)(c), the minor's provisional
1524	patient card renews automatically at the time the minor's parent or legal guardian
1525	renews the parent or legal guardian's associated medical cannabis guardian card.
1526	(7)(a) A cardholder under this section shall carry the cardholder's valid medical cannabis

1527	card with the patient's name.
1528	(b)(i) A medical cannabis patient cardholder or a provisional patient cardholder may
1529	purchase, in accordance with this part and the recommendation underlying the
1530	card, cannabis in a medicinal dosage form, a cannabis product in a medicinal
1531	dosage form, or a medical cannabis device.
1532	(ii) A cardholder under this section may possess or transport, in accordance with this
1533	part and the recommendation underlying the card, cannabis in a medicinal dosage
1534	form, a cannabis product in a medicinal dosage form, or a medical cannabis
1535	device.
1536	(iii) To address the qualifying condition underlying the medical cannabis treatment
1537	recommendation:
1538	(A) a medical cannabis patient cardholder or a provisional patient cardholder may
1539	use medical cannabis or a medical cannabis device; and
1540	(B) a medical cannabis guardian cardholder may assist the associated provisional
1541	patient cardholder with the use of medical cannabis or a medical cannabis
1542	device.
1543	(8)(a) The department may revoke a medical cannabis card that the department issues
1544	under this section if:
1545	(i) the recommending medical provider withdraws the medical provider's
1546	recommendation for medical cannabis; or
1547	(ii) the cardholder:
1548	(A) violates this part; or
1549	(B) is convicted under state or federal law of, after March 17, 2021, a drug
1550	distribution offense.
1551	(b) The department may not refuse to issue a medical cannabis card to a patient solely
1552	based on a prior revocation under Subsection (8)(a)(i).
1553	(9) The department shall establish by rule, in accordance with Title 63G, Chapter 3, Utah
1554	Administrative Rulemaking Act, a process to provide information regarding the
1555	following to an individual receiving a medical cannabis card:
1556	(a) risks associated with medical cannabis treatment;
1557	(b) the fact that a condition's listing as a qualifying condition does not suggest that
1558	medical cannabis treatment is an effective treatment or cure for that condition, as
1559	described in Subsection 26B-4-203(1); and
1560	(c) other relevant warnings and safety information that the department determines.

1561	(10) The department may establish procedures by rule, in accordance with Title 63G,
1562	Chapter 3, Utah Administrative Rulemaking Act, to implement the application and
1563	issuance provisions of this section.
1564	(11)(a) The department shall establish by rule, in accordance with Title 63G, Chapter 3,
1565	Utah Administrative Rulemaking Act, a process to allow an individual from another
1566	state to register with the department in order to purchase medical cannabis or a
1567	medical cannabis device from a medical cannabis pharmacy while the individual is
1568	visiting the state.
1569	(b) The department may only provide the registration process described in Subsection
1570	(11)(a):
1571	(i) to a nonresident patient; and
1572	(ii) for no more than two visitation periods per calendar year of up to 21 calendar
1573	days per visitation period.
1574	(12)(a) A person may submit to the department a request to conduct a research study
1575	using medical cannabis cardholder data that the state electronic verification system
1576	contains.
1577	(b) The department shall review a request described in Subsection (12)(a) to determine
1578	whether an institutional review board, as that term is defined in Section 26B-4-201,
1579	could approve the research study.
1580	(c) At the time an individual applies for a medical cannabis card, the department shall
1581	notify the individual:
1582	(i) of how the individual's information will be used as a cardholder;
1583	(ii) that by applying for a medical cannabis card, unless the individual withdraws
1584	consent under Subsection (12)(d), the individual consents to the use of the
1585	individual's information for external research; and
1586	(iii) that the individual may withdraw consent for the use of the individual's
1587	information for external research at any time, including at the time of application.
1588	(d) An applicant may, through the medical cannabis card application, and a medical
1589	cannabis cardholder may, through the state central patient portal, withdraw the
1590	applicant's or cardholder's consent to participate in external research at any time.
1591	(e) The department may release, for the purposes of a study described in this Subsection
1592	(12), information about a cardholder under this section who consents to participate
1593	under Subsection (12)(c).
1594	(f) If an individual withdraws consent under Subsection (12)(d), the withdrawal of

1595	consent:
1596	(i) applies to external research that is initiated after the withdrawal of consent; and
1597	(ii) does not apply to research that was initiated before the withdrawal of consent.
1598	(g) The department may establish standards for a medical research study's validity, by
1599	rule made in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking
1600	Act.
1601	(13) The department shall record the issuance or revocation of a medical cannabis card
1602	under this section in the controlled substance database.
1603	Section 12. Section <b>26B-4-214</b> is amended to read:
1604	26B-4-214 . Medical cannabis caregiver card Registration Renewal
1605	Revocation.
1606	(1)(a) A cardholder described in Section 26B-4-213 may designate, through the state
1607	central patient portal, up to two individuals, or an individual and a facility in
1608	accordance with Subsection (1)(b), to serve as a designated caregiver for the
1609	cardholder.
1610	(b)(i) A cardholder described in Section 26B-4-213 may designate one of the
1611	following types of facilities as one of the caregivers described in Subsection (1)(a):
1612	(A) for a patient or resident, an assisted living facility, as that term is defined in
1613	Section 26B-2-201;
1614	(B) for a patient or resident, a nursing care facility, as that term is defined in
1615	Section 26B-2-201; or
1616	(C) for a patient, a general acute hospital, as that term is defined in Section
1617	26B-2-201.
1618	(ii) A facility may:
1619	(A) assign one or more employees to assist patients with medical cannabis
1620	treatment under the caregiver designation described in this Subsection (1)(b);
1621	and
1622	(B) receive a medical cannabis shipment from a medical cannabis pharmacy or a
1623	medical cannabis courier on behalf of the medical cannabis cardholder within
1624	the facility who designated the facility as a caregiver.
1625	(iii) The department shall make rules to regulate the practice of facilities and facility
1626	employees serving as designated caregivers under this Subsection (1)(b).
1627	(c) A parent or legal guardian described in Subsection 26B-4-213(2)(d), in consultation
1628	with the minor and the minor's [qualified medical provider] recommending medical

1629	provider, may designate, through the state central patient portal, up to two individuals
1630	to serve as a designated caregiver for the minor, if the department determines that the
1631	parent or legal guardian is not eligible for a medical cannabis guardian card under
1632	Section 26B-4-213.
1633	(d)(i) Upon the entry of a caregiver designation under Subsection $(1)(\underline{c})$ by a patient
1634	with a terminal illness described in Section 26B-4-203, the department shall issue
1635	to the designated caregiver an electronic conditional medical cannabis caregiver
1636	card, in accordance with this Subsection (1)(d).
1637	(ii) A conditional medical cannabis caregiver card is valid for the lesser of:
1638	(A) 60 days; or
1639	(B) the day on which the department completes the department's review and issues
1640	a medical cannabis caregiver card under Subsection (1)(a), denies the patient's
1641	medical cannabis caregiver card application, or revokes the conditional
1642	medical cannabis caregiver card under 26B-4-246.
1643	(iii) The department may issue a conditional medical cannabis card to an individual
1644	applying for a medical cannabis patient card for which approval of the
1645	Compassionate Use Board is not required.
1646	(iv) An individual described in Subsection (1)(b)(iii) has the rights, restrictions, and
1647	obligations under law applicable to a holder of the medical cannabis card for
1648	which the individual applies and for which the department issues the conditional
1649	medical cannabis card.
1650	(2) An individual that the department registers as a designated caregiver under this section
1651	and a facility described in Subsection (1)(b):
1652	(a) for an individual designated caregiver, may carry a valid medical cannabis caregiver
1653	card;
1654	(b) in accordance with this part, may purchase, possess, transport, or assist the patient in
1655	the use of cannabis in a medicinal dosage form, a cannabis product in a medicinal
1656	dosage form, or a medical cannabis device on behalf of the designating medical
1657	cannabis cardholder;
1658	(c) may not charge a fee to an individual to act as the individual's designated caregiver
1659	or for a service that the designated caregiver provides in relation to the role as a
1660	designated caregiver; and
1661	(d) may accept reimbursement from the designating medical cannabis cardholder for
1662	direct costs the designated caregiver incurs for assisting with the designating

1663	cardholder's medicinal use of cannabis.
1664	(3)(a) The department shall:
1665	(i) within 15 days after the day on which an individual submits an application in
1666	compliance with this section, issue a medical cannabis card to the applicant if the
1667	applicant:
1668	(A) is designated as a caregiver under Subsection (1);
1669	(B) is eligible for a medical cannabis caregiver card under Subsection (4); and
1670	(C) complies with this section; and
1671	(ii) notify the Department of Public Safety of each individual that the department
1672	registers as a designated caregiver.
1673	(b) The department shall ensure that a medical cannabis caregiver card contains the
1674	information described in Subsections (5)(b) and (3)(c)(i).
1675	(c) If a cardholder described in Section 26B-4-213 designates an individual as a
1676	caregiver who already holds a medical cannabis caregiver card, the individual with
1677	the medical cannabis caregiver card:
1678	(i) shall report to the department the information required of applicants under
1679	Subsection (5)(b) regarding the new designation;
1680	(ii) if the individual makes the report described in Subsection (3)(c)(i), is not required
1681	to file an application for another medical cannabis caregiver card;
1682	(iii) may receive an additional medical cannabis caregiver card in relation to each
1683	additional medical cannabis patient who designates the caregiver; and
1684	(iv) is not subject to an additional background check.
1685	(4) An individual is eligible for a medical cannabis caregiver card if the individual:
1686	(a) is at least 21 years old;
1687	(b) is a Utah resident;
1688	(c) pays to the department a fee in an amount that, subject to Subsection 26B-1-310(5),
1689	the department sets in accordance with Section 63J-1-504, plus the cost of the
1690	criminal background check described in Section 26B-4-215;
1691	(d) signs an acknowledgment stating that the applicant received the information
1692	described in Subsection 26B-4-213(9).
1693	(5) An eligible applicant for a medical cannabis caregiver card shall:
1694	(a) submit an application for a medical cannabis caregiver card to the department
1695	through an electronic application connected to the state electronic verification
1696	system; and

1697	(b) submit the following information in the application described in Subsection (5)(a):
1698	(i) the applicant's name, gender, age, and address;
1699	(ii) the name, gender, age, and address of the cardholder described in Section
1700	26B-4-213 who designated the applicant;
1701	(iii) if a medical cannabis guardian cardholder designated the caregiver, the name,
1702	gender, and age of the minor receiving a medical cannabis treatment in relation to
1703	the medical cannabis guardian cardholder; and
1704	(iv) any additional information that the department requests to assist in matching the
1705	application with the designating medical cannabis patient.
1706	(6) Except as provided in Subsection (6)(b), a medical cannabis caregiver card that the
1707	department issues under this section is valid for the lesser of:
1708	(a) an amount of time that the cardholder described in Section 26B-4-213 who
1709	designated the caregiver determines; or
1710	(b) the amount of time remaining before the card of the cardholder described in Section
1711	26B-4-213 expires.
1712	(7)(a) If a designated caregiver meets the requirements of Subsection (4), the designated
1713	caregiver's medical cannabis caregiver card renews automatically at the time the
1714	cardholder described in Section 26B-4-213 who designated the caregiver:
1715	(i) renews the cardholder's card; and
1716	(ii) renews the caregiver's designation, in accordance with Subsection (7)(b).
1717	(b) The department shall provide a method in the card renewal process to allow a
1718	cardholder described in Section 26B-4-213 who has designated a caregiver to:
1719	(i) signify that the cardholder renews the caregiver's designation;
1720	(ii) remove a caregiver's designation; or
1721	(iii) designate a new caregiver.
1722	(8) The department shall record the issuance or revocation of a medical cannabis card under
1723	this section in the controlled substance database.
1724	Section 13. Section <b>26B-4-231</b> is amended to read:
1725	26B-4-231 . Partial filling Pharmacy medical provider directions of use.
1726	(1) As used in this section, "partially fill" means to provide less than the full amount of
1727	cannabis or cannabis product that the recommending medical provider recommends, if
1728	the recommending medical provider recommended specific dosing guidelines.
1729	(2) A pharmacy medical provider may partially fill a recommendation for a medical
1730	cannabis treatment at the request of the recommending medical provider who issued the

1731	medical cannabis treatment recommendation or the medical cannabis cardholder.
1732	(3) The department shall make rules, in collaboration with the Division of Professional
1733	Licensing and the Board of Pharmacy and in accordance with Title 63G, Chapter 3, Utah
1734	Administrative Rulemaking Act, specifying how to record the date, quantity supplied,
1735	and quantity remaining of a partially filled medical cannabis treatment recommendation.
1736	(4) A pharmacy medical provider who is a pharmacist may, upon the request of a medical
1737	cannabis cardholder, determine different dosing guidelines, subject to the dosing limits
1738	in Subsection 4-41a-1102(2), to fill the quantity remaining of a partially filled medical
1739	cannabis treatment recommendation if:
1740	(a) the pharmacy medical provider determined dosing guidelines for the partial fill under
1741	Subsection 4-41a-1102(5) or (6); and
1742	(b) the medical cannabis cardholder reports that:
1743	(i) the partial fill did not substantially affect the qualifying condition underlying the
1744	medical cannabis recommendation; or
1745	(ii) the patient experienced an adverse reaction to the partial fill or was otherwise
1746	unable to successfully use the partial fill.
1747	(5) If a recommending medical provider recommends treatment with medical cannabis but
1748	wishes for the pharmacy medical provider to determine directions of use and dosing
1749	guidelines:
1750	(a) the recommending medical provider shall provide to the pharmacy medical provider,
1751	either through the state electronic verification system or through a medical cannabis
1752	pharmacy's recording of a recommendation under the order of a [limited medical
1753	provider] recommending medical provider, any of the following information that the
1754	recommending medical provider feels would be needed to provide appropriate
1755	directions of use and dosing guidelines:
1756	(i) information regarding the qualifying condition underlying the recommendation;
	(-)
1757	(ii) information regarding prior treatment attempts with medical cannabis; and
1757 1758	
	(ii) information regarding prior treatment attempts with medical cannabis; and
1758	<ul><li>(ii) information regarding prior treatment attempts with medical cannabis; and</li><li>(iii) portions of the patient's current medication list; and</li></ul>
1758 1759	<ul> <li>(ii) information regarding prior treatment attempts with medical cannabis; and</li> <li>(iii) portions of the patient's current medication list; and</li> <li>(b) before the relevant medical cannabis cardholder may obtain medical cannabis, the</li> </ul>
1758 1759 1760	<ul> <li>(ii) information regarding prior treatment attempts with medical cannabis; and</li> <li>(iii) portions of the patient's current medication list; and</li> <li>(b) before the relevant medical cannabis cardholder may obtain medical cannabis, the pharmacy medical provider shall:</li> </ul>
1758 1759 1760 1761	<ul> <li>(ii) information regarding prior treatment attempts with medical cannabis; and</li> <li>(iii) portions of the patient's current medication list; and</li> <li>(b) before the relevant medical cannabis cardholder may obtain medical cannabis, the pharmacy medical provider shall:</li> <li>(i) review pertinent medical records, including the recommending medical provider</li> </ul>

1765	treatment through consultation with the cardholder regarding:
1766	(A) the patient's qualifying condition underlying the recommendation from the
1767	recommending medical provider;
1768	(B) indications for available treatments;
1769	(C) directions of use and dosing guidelines; and
1770	(D) potential adverse reactions.
1771	Section 14. Section <b>26B-4-245</b> is amended to read:
1772	26B-4-245 . Purchasing and use limitations.
1773	(1) An individual with a medical cannabis card:
1774	(a) may purchase, in any one 28-day period, up to the legal dosage limit of:
1775	(i) unprocessed cannabis in a medicinal dosage form; and
1776	(ii) a cannabis product in a medicinal dosage form;
1777	(b) may not purchase:
1778	(i) except as provided in Subsection (2), more medical cannabis than described in
1779	Subsection (1)(a); or
1780	(ii) if the relevant recommending medical provider did not recommend directions of
1781	use and dosing guidelines, until the individual consults with the pharmacy medical
1782	provider in accordance with Subsection 26B-4-231(5), any medical cannabis; and
1783	(c) may not use a route of administration that the relevant recommending medical
1784	provider or the pharmacy medical provider, in accordance with Subsection 26B-4-231
1785	(5), has not recommended.
1786	(2)(a) A [qualified medical provider] recommending medical provider may petition the
1787	department to waive the 28-day period limit described in Subsection (1)(a) for a
1788	medical cannabis cardholder if the medical cannabis cardholder:
1789	(i) has been diagnosed with a terminal illness;
1790	(ii) has a life expectancy of six months or less; and
1791	(iii) needs the waiver for palliative purposes.
1792	(b) The department shall:
1793	(i) consult with the Compassionate Use Board to determine whether the waiver
1794	should be granted;
1795	(ii) issue a response to the petition within 10 days from the day on which the petition
1796	is received.
1797	(c) The department may waive the 28-day period limit for no more than 180 days.
1798	(d) A petition described in this Subsection (2) may be combined with the petition

1799	described in Subsection 26B-1-421(6).
1800	Section 15. Section <b>58-1-513</b> is enacted to read:
1801	58-1-513 . Recommending medical provider cannabis advertisement Payment
1802	restriction Unprofessional conduct.
1803	(1) As used in this section:
1804	(a) "Recommending medical provider" means the same as that term is defined in Section
1805	<u>26B-4-201.</u>
1806	(b) <u>"Targeted marketing" means the same as that term is defined in Section 26B-4-201.</u>
1807	(2)(a) Except as provided in Subsections (2)(b) and (c), a person may not advertise that
1808	the person or the person's employee recommends a medical cannabis treatment.
1809	(b) Notwithstanding Subsection (2)(a) and Section 4-41a-109, a recommending medical
1810	provider, medical clinic, or medical office that employs a recommending medical
1811	provider may advertise only the following:
1812	(i) a green cross;
1813	(ii) the provider's or clinic's name and logo;
1814	(iii) a qualifying condition that the individual treats:
1815	(iv) that the recommending medical provider, medical clinic, or medical office
1816	evaluates patients for medical cannabis recommendations;
1817	(v) a scientific study regarding medical cannabis use; or
1818	(vi) contact information.
1819	(c) Notwithstanding Subsection (2)(a) and Section 4-41a-109, a recommending medical
1820	provider, medical clinic, or medical office that employs a recommending medical
1821	provider may engage in targeted marketing, as determined by the Department of
1822	Health and Human Services through rule, for advertising medical cannabis
1823	recommendation services.
1824	(3)(a) A recommending medical provider may not:
1825	(i) receive any compensation or benefit for the recommending medical provider's
1826	medical cannabis treatment recommendation from:
1827	(A) a cannabis production establishment or an owner, officer, director, board
1828	member, employee, or agent of a cannabis production establishment;
1829	(B) a medical cannabis pharmacy or an owner, officer, director, board member,
1830	employee, or agent of a medical cannabis pharmacy; or
1831	(C) a recommending medical provider or pharmacy medical provider; or
1832	(ii) provide a medical cannabis recommendation at a medical clinic or medical office

1833	that is violating the advertising limitations described in Subsection (2).
1834	(b) A violation of Subsection (3)(a) is unprofessional conduct.
1835	Section 16. Section <b>58-5a-102</b> is amended to read:
1836	58-5a-102 . Definitions.
1837	In addition to the definitions under Section 58-1-102, as used in this chapter:
1838	(1) "Assisted living facility" means the same as that term is defined in Section 26B-2-201.
1839	(2) "Board" means the Podiatric Physician Board created in Section 58-5a-201.
1840	(3) "Indirect supervision" means the same as that term is defined by the division by rule
1841	made in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act.
1842	(4) "Medical assistant" means an unlicensed individual working under the indirect
1843	supervision of a licensed podiatric physician and engaging in specific tasks assigned by
1844	the licensed podiatric physician in accordance with the standards and ethics of the
1845	podiatry profession.
1846	(5) "Practice of podiatry" means, subject to Section 58-5a-103, the diagnosis and treatment
1847	of conditions affecting the human foot and ankle and their manifestations of systemic
1848	conditions, and wound debridement on the limbs and torso, by all appropriate and lawful
1849	means.
1850	(6) "Unlawful conduct" includes:
1851	(a) the conduct that constitutes unlawful conduct under Section 58-1-501; and
1852	(b) for an individual who is not licensed under this chapter:
1853	(i) using the title or name podiatric physician, podiatrist, podiatric surgeon, foot
1854	doctor, foot specialist, or D.P.M.; or
1855	(ii) implying or representing that the individual is qualified to practice podiatry.
1856	(7)(a) "Unprofessional conduct" includes, for an individual licensed under this chapter:
1857	(i) the conduct that constitutes unprofessional conduct under Section 58-1-501;
1858	(ii) communicating to a third party, without the consent of the patient, information
1859	the individual acquires in treating the patient, except as necessary for professional
1860	consultation regarding treatment of the patient;
1861	(iii) allowing the individual's name or license to be used by an individual who is not
1862	licensed to practice podiatry under this chapter;
1863	(iv) except as described in Section 58-5a-306, employing, directly or indirectly, any
1864	unlicensed individual to practice podiatry;
1865	(v) using alcohol or drugs, to the extent the individual's use of alcohol or drugs
1866	impairs the individual's ability to practice podiatry;

1867	(vi) unlawfully prescribing, selling, or giving away any prescription drug, including
1868	controlled substances, as defined in Section 58-37-2;
1869	(vii) gross incompetency in the practice of podiatry;
1870	(viii) willfully and intentionally making a false statement or entry in hospital records,
1871	medical records, or reports;
1872	(ix) willfully making a false statement in reports or claim forms to governmental
1873	agencies or insurance companies with the intent to secure payment not rightfully
1874	due;
1875	(x) willfully using false or fraudulent advertising;
1876	(xi) conduct the division defines as unprofessional conduct by rule made in
1877	accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act;
1878	(xii) falsely making an entry in, or altering, a medical record with the intent to
1879	conceal:
1880	(A) a wrongful or negligent act or omission of an individual licensed under this
1881	chapter or an individual under the direction or control of an individual licensed
1882	under this chapter; or
1883	(B) conduct described in Subsections (7)(a)(i) through (xi) or Subsection 58-1-501
1884	(1); or
1885	(xiii) violating the requirements of Title 26B, Chapter 4, Part 2, Cannabinoid
1886	Research and Medical Cannabis.
1887	(b) "Unprofessional conduct" does not include, in accordance with Title 26B, Chapter 4,
1888	Part 2, Cannabinoid Research and Medical Cannabis, when [registered as a
1889	qualified medical provider or acting as a limited medical provider, as those terms are]
1890	acting as a recommending medical provider, as that term is defined in Section
1891	26B-4-201, recommending the use of medical cannabis within the scope of a practice
1892	of podiatry.
1893	Section 17. Section <b>58-31b-305</b> is amended to read:
1894	58-31b-305 . Term of license Expiration Renewal.
1895	(1)(a) The division shall issue each license or certification under this chapter in
1896	accordance with a two-year renewal cycle established by rule.
1897	(b) The division may by rule extend or shorten a renewal period by as much as one year
1898	to stagger the renewal cycles the division administers.
1899	(2) The division shall renew the license of a licensee who, at the time of renewal:
1900	(a) completes and submits an application for renewal in a form prescribed by the

1901	division;
1902	(b) pays a renewal fee established by the division under Section 63J-1-504;
1903	(c) views a suicide prevention video described in Section 58-1-601 and submits proof in
1904	the form required by the division; and
1905	(d) meets continuing competency requirements as established by rule.
1906	(3) In addition to the renewal requirements under Subsection (2), a person licensed as an
1907	advanced practice registered nurse shall be currently certified by a program approved by
1908	the division in collaboration with the board and submit evidence satisfactory to the
1909	division of that qualification or if licensed prior to July 1, 1992, meet the requirements
1910	established by rule.
1911	(4) In addition to the requirements described in Subsections (2) and (3), an advanced
1912	practice registered nurse licensee specializing in psychiatric mental health nursing who,
1913	as of the day on which the division originally issued the licensee's license had not
1914	completed the division's clinical practice requirements in psychiatric and mental health
1915	nursing, shall, to qualify for renewal:
1916	(a) if renewing less than two years after the day on which the division originally issued
1917	the license, demonstrate satisfactory progress toward completing the clinical practice
1918	requirements; or
1919	(b) have completed the clinical practice requirements.
1920	(5) Each license or certification automatically expires on the expiration date shown on the
1921	license or certification unless renewed in accordance with Section 58-1-308.
1922	[(6) The division shall accept and apply toward an hour requirement that the division
1923	establishes under Subsection (2)(d) continuing education that an advanced practice
1924	registered nurse completes in accordance with Section 26B-4-204.]
1925	Section 18. Section <b>58-31b-502</b> is amended to read:
1926	58-31b-502 . Unprofessional conduct.
1927	(1) "Unprofessional conduct" includes:
1928	(a) failure to safeguard a patient's right to privacy as to the patient's person, condition,
1929	diagnosis, personal effects, or any other matter about which the licensee is privileged
1930	to know because of the licensee's or person with a certification's position or practice
1931	as a nurse or practice as a medication aide certified;
1932	(b) failure to provide nursing service or service as a medication aide certified in a
1933	manner that demonstrates respect for the patient's human dignity and unique personal
1934	character and needs without regard to the patient's race, religion, ethnic background,

1935	socioeconomic status, age, sex, or the nature of the patient's health problem;
1936	(c) engaging in sexual relations with a patient during any:
1937	(i) period when a generally recognized professional relationship exists between the
1938	person licensed or certified under this chapter and the patient; or
1939	(ii) extended period when a patient has reasonable cause to believe a professional
1940	relationship exists between the person licensed or certified under the provisions of
1941	this chapter and the patient;
1942	(d)(i) as a result of any circumstance under Subsection (1)(c), exploiting or using
1943	information about a patient or exploiting the licensee's or the person with a
1944	certification's professional relationship between the licensee or holder of a
1945	certification under this chapter and the patient; or
1946	(ii) exploiting the patient by use of the licensee's or person with a certification's
1947	knowledge of the patient obtained while acting as a nurse or a medication aide
1948	certified;
1949	(e) unlawfully obtaining, possessing, or using any prescription drug or illicit drug;
1950	(f) unauthorized taking or personal use of nursing supplies from an employer;
1951	(g) unauthorized taking or personal use of a patient's personal property;
1952	(h) unlawful or inappropriate delegation of nursing care;
1953	(i) failure to exercise appropriate supervision of persons providing patient care services
1954	under supervision of the licensed nurse;
1955	(j) employing or aiding and abetting the employment of an unqualified or unlicensed
1956	person to practice as a nurse;
1957	(k) failure to file or record any medical report as required by law, impeding or
1958	obstructing the filing or recording of such a report, or inducing another to fail to file
1959	or record such a report;
1960	(1) breach of a statutory, common law, regulatory, or ethical requirement of
1961	confidentiality with respect to a person who is a patient, unless ordered by a court;
1962	(m) failure to pay a penalty imposed by the division;
1963	(n) violating Section 58-31b-801;
1964	(o) violating the dispensing requirements of Section 58-17b-309 or Chapter 17b, Part 8,
1965	Dispensing Medical Practitioner and Dispensing Medical Practitioner Clinic
1966	Pharmacy, if applicable;
1967	(p) performing or inducing an abortion in violation of the requirements of Section
1968	76-7-302 or Section 76-7a-201, regardless of whether the person licensed or certified

1969	under the provisions of this chapter is found guilty of a crime in connection with the
1970	violation;
1971	(q) falsely making an entry in, or altering, a medical record with the intent to conceal:
1972	(i) a wrongful or negligent act or omission of an individual licensed under this
1973	chapter or an individual under the direction or control of an individual licensed
1974	under this chapter; or
1975	(ii) conduct described in Subsections (1)(a) through (n) or Subsection 58-1-501(1);
1976	(r) violating the requirements of Title 26B, Chapter 4, Part 2, Cannabinoid Research and
1977	Medical Cannabis; or
1978	(s) for an advance practice registered nurse, designating a child as do not resuscitate
1979	without parental consent.
1980	(2) "Unprofessional conduct" does not include, in accordance with Title 26B, Chapter 4,
1981	Part 2, Cannabinoid Research and Medical Cannabis, when [registered as a qualified
1982	medical provider, or acting as a limited medical provider, as those terms are] acting as a
1983	recommending medical provider, as that term is defined in Section 26B-4-201,
1984	recommending the use of medical cannabis.
1985	(3) Notwithstanding Subsection (2), the division, in consultation with the board and in
1986	accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, shall
1987	define unprofessional conduct for an advanced practice registered nurse described in
1988	Subsection (2).
1989	Section 19. Section 58-67-304 is amended to read:
1990	58-67-304 . License renewal requirements.
1991	(1) As a condition precedent for license renewal, each licensee shall, during each two-year
1992	licensure cycle or other cycle defined by division rule:
1993	(a) complete qualified continuing professional education requirements in accordance
1994	with the number of hours and standards defined by division rule made in
1995	collaboration with the board;
1996	(b) appoint a contact person for access to medical records and an alternate contact
1997	person for access to medical records in accordance with Subsection 58-67-302(1)(i);
1998	(c) if the licensee practices medicine in a location with no other persons licensed under
1999	this chapter, provide some method of notice to the licensee's patients of the identity
2000	and location of the contact person and alternate contact person for the licensee; and
2001	(d) if the licensee is an associate physician licensed under Section 58-67-302.8,
2002	successfully complete the educational methods and programs described in Subsection

2003	58-67-807(4).
2004	(2) If a renewal period is extended or shortened under Section 58-67-303, the continuing
2005	education hours required for license renewal under this section are increased or
2006	decreased proportionally.
2007	(3)(a) An application to renew a license under this chapter shall:
2008	(i) require a physician to answer the following question: "Do you perform elective
2009	abortions in Utah in a location other than a hospital?"; and
2010	(ii) immediately following the question, contain the following statement: "For
2011	purposes of the immediately preceding question, elective abortion means an
2012	abortion other than one of the following: removal of a dead fetus, removal of an
2013	ectopic pregnancy, an abortion that is necessary to avert the death of a woman, an
2014	abortion that is necessary to avert a serious physical risk of substantial impairment
2015	of a major bodily function of a woman, an abortion of a fetus that has a defect that
2016	is uniformly diagnosable and uniformly lethal, or an abortion where the woman is
2017	pregnant as a result of rape or incest."
2018	(b) The statement in Subsection (3)(a)(ii) shall be modified, if necessary, to ensure
2019	compliance with the definitions and requirements of Title 76, Chapter 7, Part 3,
2020	Abortion, and Title 76, Chapter 7a, Abortion Prohibition.
2021	(4) In order to assist the Department of Health and Human Services in fulfilling the
2022	department's responsibilities relating to the licensing of a health care facility and the
2023	enforcement of Title 76, Chapter 7, Part 3, Abortion, and Title 76, Chapter 7a, Abortion
2024	Prohibition, if a physician responds positively to the question described in Subsection
2025	(3)(a)(i) the division shall, within 30 days after the day on which the division renews the
2026	physician's license under this chapter, inform the Department of Health and Human
2027	Services in writing:
2028	(a) of the name and business address of the physician; and
2029	(b) that the physician responded positively to the question described in Subsection
2030	(3)(a)(i).
2031	(5) The division shall accept and apply toward the hour requirement in Subsection (1)(a)
2032	any continuing education that a physician completes in accordance with [Sections
2033	<del>26B-4-204 and</del> ] <u>Section</u> 26B-4-219.
2034	Section 20. Section <b>58-67-502</b> is amended to read:
2035	58-67-502 . Unprofessional conduct.
2036	(1) "Unprofessional conduct" includes, in addition to the definition in Section 58-1-501:

2037	(a) using or employing the services of any individual to assist a licensee in any manner
2038	not in accordance with the generally recognized practices, standards, or ethics of the
2039	profession, state law, or division rule;
2040	(b) making a material misrepresentation regarding the qualifications for licensure under
2041	Section 58-67-302.7 or 58-67-302.8;
2042	(c) violating the dispensing requirements of Chapter 17b, Part 8, Dispensing Medical
2043	Practitioner and Dispensing Medical Practitioner Clinic Pharmacy, if applicable;
2044	(d) violating the requirements of Title 26B, Chapter 4, Part 2, Cannabinoid Research and
2045	Medical Cannabis;
2046	(e) performing or inducing an abortion in violation of the requirements of Section
2047	76-7-302 or Section 76-7a-201, regardless of whether the individual licensed under
2048	this chapter is found guilty of a crime in connection with the violation;
2049	(f) falsely making an entry in, or altering, a medical record with the intent to conceal:
2050	(i) a wrongful or negligent act or omission of an individual licensed under this
2051	chapter or an individual under the direction or control of an individual licensed
2052	under this chapter; or
2053	(ii) conduct described in Subsections (1)(a) through (e) or Subsection 58-1-501(1);
2054	(g) performing, or causing to be performed, upon an individual who is less than 18 years
2055	old:
2056	(i) a primary sex characteristic surgical procedure; or
2057	(ii) a secondary sex characteristic surgical procedure; or
2058	(h) designating a child as do not resuscitate without parental consent.
2059	(2) "Unprofessional conduct" does not include:
2060	(a) in compliance with Section 58-85-103:
2061	(i) obtaining an investigational drug or investigational device;
2062	(ii) administering the investigational drug to an eligible patient; or
2063	(iii) treating an eligible patient with the investigational drug or investigational device;
2064	or
2065	(b) in accordance with Title 26B, Chapter 4, Part 2, Cannabinoid Research and Medical
2066	Cannabis:
2067	(i) when [registered as a qualified medical provider or acting as a limited medical
2068	provider, as those terms are ] acting as a recommending medical provider, as that
2069	term is defined in Section 26B-4-201, recommending the use of medical cannabis;
2070	or

2071	(ii) when registered as a pharmacy medical provider, as that term is defined in
2072	Section 26B-4-201, providing pharmacy medical provider services in a medical
2073	cannabis pharmacy.
2074	(3) Notwithstanding Subsection (2)(b), the division, in consultation with the board and in
2075	accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, shall
2076	define unprofessional conduct for a physician described in Subsection (2)(b).
2077	Section 21. Section 58-68-304 is amended to read:
2078	58-68-304 . License renewal requirements.
2079	(1) As a condition precedent for license renewal, each licensee shall, during each two-year
2080	licensure cycle or other cycle defined by division rule:
2081	(a) complete qualified continuing professional education requirements in accordance
2082	with the number of hours and standards defined by division rule in collaboration with
2083	the board;
2084	(b) appoint a contact person for access to medical records and an alternate contact
2085	person for access to medical records in accordance with Subsection 58-68-302(1)(i);
2086	(c) if the licensee practices osteopathic medicine in a location with no other persons
2087	licensed under this chapter, provide some method of notice to the licensee's patients
2088	of the identity and location of the contact person and alternate contact person for
2089	access to medical records for the licensee in accordance with Subsection
2090	58-68-302(1)(j); and
2091	(d) if the licensee is an associate physician licensed under Section 58-68-302.5,
2092	successfully complete the educational methods and programs described in Subsection
2093	58-68-807(4).
2094	(2) If a renewal period is extended or shortened under Section 58-68-303, the continuing
2095	education hours required for license renewal under this section are increased or
2096	decreased proportionally.
2097	(3)(a) An application to renew a license under this chapter shall:
2098	(i) require a physician to answer the following question: "Do you perform elective
2099	abortions in Utah in a location other than a hospital?"; and
2100	(ii) immediately following the question, contain the following statement: "For
2101	purposes of the immediately preceding question, elective abortion means an
2102	abortion other than one of the following: removal of a dead fetus, removal of an
2103	ectopic pregnancy, an abortion that is necessary to avert the death of a woman, an
2104	abortion that is necessary to avert a serious physical risk of substantial impairment

2105	of a major bodily function of a woman, an abortion of a fetus that has a defect that
2106	is uniformly diagnosable and uniformly lethal, or an abortion where the woman is
2107	pregnant as a result of rape or incest."
2108	(b) The statement in Subsection (3)(a)(ii) shall be modified, if necessary, to ensure
2109	compliance with the definitions and requirements of Title 76, Chapter 7, Part 3,
2110	Abortion, and Title 76, Chapter 7a, Abortion Prohibition.
2111	(4) In order to assist the Department of Health and Human Services in fulfilling the
2112	department's responsibilities relating to the licensing of a health care facility and the
2113	enforcement of Title 76, Chapter 7, Part 3, Abortion, and Title 76, Chapter 7a, Abortion
2114	Prohibition, if a physician responds positively to the question described in Subsection
2115	(3)(a)(i), the division shall, within 30 days after the day on which it renews the
2116	physician's license under this chapter, inform the Department of Health and Human
2117	Services in writing:
2118	(a) of the name and business address of the physician; and
2119	(b) that the physician responded positively to the question described in Subsection
2120	(3)(a)(i).
2121	(5) The division shall accept and apply toward the hour requirement in Subsection (1)(a)
2122	any continuing education that a physician completes in accordance with [Sections
2123	<del>26B-4-204 and</del> ] <u>Section</u> 26B-4-219.
2124	Section 22. Section <b>58-68-502</b> is amended to read:
2125	58-68-502 . Unprofessional conduct.
2126	(1) "Unprofessional conduct" includes, in addition to the definition in Section 58-1-501:
2127	(a) using or employing the services of any individual to assist a licensee in any manner
2128	not in accordance with the generally recognized practices, standards, or ethics of the
2129	profession, state law, or division rule;
2130	(b) violating the dispensing requirements of Chapter 17b, Part 8, Dispensing Medical
2131	Practitioner and Dispensing Medical Practitioner Clinic Pharmacy, if applicable;
2132	(c) making a material misrepresentation regarding the qualifications for licensure under
2133	Section 58-68-302.5;
2134	(d) violating the requirements of Title 26B, Chapter 4, Part 2, Cannabinoid Research and
2135	Medical Cannabis;
2136	(e) performing or inducing an abortion in violation of the requirements of Section
2137	76-7-302 or Section 76-7a-201, regardless of whether the individual licensed under
2138	this chapter is found guilty of a crime in connection with the violation;

2139	(f) falsely making an entry in, or altering, a medical record with the intent to conceal:
2140	(i) a wrongful or negligent act or omission of an individual licensed under this
2141	chapter or an individual under the direction or control of an individual licensed
2142	under this chapter; or
2143	(ii) conduct described in Subsections (1)(a) through (e) or Subsection 58-1-501(1);
2144	(g) performing or causing to be performed, upon an individual who is less than 18 years
2145	old:
2146	(i) a primary sex characteristic surgical procedure; or
2147	(ii) a secondary sex characteristic surgical procedure; or
2148	(h) designating a child as do not resuscitate without parental consent.
2149	(2) "Unprofessional conduct" does not include:
2150	(a) in compliance with Section 58-85-103:
2151	(i) obtaining an investigational drug or investigational device;
2152	(ii) administering the investigational drug to an eligible patient; or
2153	(iii) treating an eligible patient with the investigational drug or investigational device;
2154	or
2155	(b) in accordance with Title 26B, Chapter 4, Part 2, Cannabinoid Research and Medical
2156	Cannabis:
2157	(i) when [registered as a qualified medical provider or acting as a limited medical
2158	provider, as those terms are] acting as a recommending medical provider, as that
2159	term is defined in Section 26B-4-201, recommending the use of medical cannabis;
2160	or
2161	(ii) when registered as a pharmacy medical provider, as that term is defined in
2162	Section 26B-4-201, providing pharmacy medical provider services in a medical
2163	cannabis pharmacy.
2164	(3) Notwithstanding Subsection (2)(b), the division, in consultation with the board and in
2165	accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, shall
2166	define unprofessional conduct for a physician described in Subsection (2)(b).
2167	Section 23. Section <b>58-70a-303</b> is amended to read:
2168	58-70a-303 . Term of license Expiration Renewal.
2169	(1)(a) The division shall issue each license under this chapter in accordance with a
2170	two-year renewal cycle established by division rule.
2171	(b) The division may by rule extend or shorten a renewal period by as much as one year
2172	to stagger the renewal cycles it administers.

2173	(2) At the time of renewal, the licensee shall show compliance with continuing education
2174	renewal requirements.
2175	(3) Each license issued under this chapter expires on the expiration date shown on the
2176	license unless renewed in accordance with Section 58-1-308.
2177	[(4) The division shall accept and apply toward an hour requirement that the division
2178	establishes under Subsection (2) continuing education that a physician assistant
2179	completes in accordance with Section 26B-4-204.]
2180	Section 24. Section <b>58-70a-503</b> is amended to read:
2181	58-70a-503 . Unprofessional conduct.
2182	(1) "Unprofessional conduct" includes:
2183	(a) violation of a patient confidence to any person who does not have a legal right and a
2184	professional need to know the information concerning the patient;
2185	(b) knowingly prescribing, selling, giving away, or directly or indirectly administering,
2186	or offering to prescribe, sell, furnish, give away, or administer any prescription drug
2187	except for a legitimate medical purpose upon a proper diagnosis indicating use of that
2188	drug in the amounts prescribed or provided;
2189	(c) prescribing prescription drugs for oneself or administering prescription drugs to
2190	oneself, except those that have been legally prescribed for the physician assistant by a
2191	licensed practitioner and that are used in accordance with the prescription order for
2192	the condition diagnosed;
2193	(d) in a practice that has physician assistant ownership interests, failure to allow a
2194	physician the independent final decision making authority on treatment decisions for
2195	the physician's patient;
2196	(e) violating the dispensing requirements of Chapter 17b, Part 8, Dispensing Medical
2197	Practitioner and Dispensing Medical Practitioner Clinic Pharmacy, if applicable;
2198	(f) falsely making an entry in, or altering, a medical record with the intent to conceal:
2199	(i) a wrongful or negligent act or omission of an individual licensed under this
2200	chapter or an individual under the direction or control of an individual licensed
2201	under this chapter; or
2202	(ii) conduct described in Subsections (1)(a) through (e) or Subsection 58-1-501(1);
2203	(g) violating the requirements of Title 26B, Chapter 4, Part 2, Cannabinoid Research and
2204	Medical Cannabis; or
2205	(h) designating a child as do not resuscitate without parental consent.
2206	(2)(a) "Unprofessional conduct" does not include, in accordance with Title 26B, Chapter

2207	4, Part 2, Cannabinoid Research and Medical Cannabis, when [registered as a
2208	qualified medical provider or acting as a limited medical provider, as those terms are]
2209	acting as a recommending medical provider, as that term is defined in Section
2210	26B-4-201, recommending the use of medical cannabis.
2211	(b) Notwithstanding Subsection (2)(a), the division, in consultation with the board and in
2212	accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, shall
2213	define unprofessional conduct for a physician assistant described in Subsection (2)(a).
2214	Section 25. Section <b>80-4-109</b> is amended to read:
2215	80-4-109 . Consideration of cannabis during proceedings.
2216	(1) As used in this section:
2217	(a) "Cannabis" means the same as that term is defined in Section 26B-4-201.
2218	(b) "Cannabis product" means the same as that term is defined in Section 26B-4-201.
2219	(c)(i) "Chronic" means repeated or patterned.
2220	(ii) "Chronic" does not mean an isolated incident.
2221	(d) "Directions of use" means the same as that term is defined in Section 26B-4-201.
2222	(e) "Dosing guidelines" means the same as that term is defined in Section 26B-4-201.
2223	(f) "Medical cannabis" means the same as that term is defined in Section 26B-4-201.
2224	(g) "Medical cannabis cardholder" means the same as that term is defined in Section
2225	26B-4-201.
2226	(h) "[Qualified] Recommending medical provider" means the same as that term is
2227	defined in Section 26B-4-201.
2228	(2) In a proceeding under this chapter in which the juvenile court makes a finding,
2229	determination, or otherwise considers an individual's possession or use of medical
2230	cannabis, a cannabis product, or a medical cannabis device, the juvenile court may not
2231	consider or treat the individual's possession or use any differently than the lawful
2232	possession or use of any prescribed controlled substance if:
2233	(a) the individual's possession or use complies with Title 4, Chapter 41a, Cannabis
2234	Production Establishments and Pharmacies;
2235	(b) the individual's possession or use complies with Subsection 58-37-3.7(2) or (3); or
2236	(c)(i) the individual's possession or use complies with Title 26B, Chapter 4, Part 2,
2237	Cannabinoid Research and Medical Cannabis; and
2238	(ii) the individual reasonably complies with the directions of use and dosing
2239	guidelines determined by the individual's [qualified medical provider]
2240	recommending medical provider or through a consultation described in Subsection

2241	26B-4-230(5).
2242	(3) In a proceeding under this chapter, a parent's or guardian's use of cannabis or a cannabis
2243	product is not abuse or neglect of a child unless there is evidence showing that:
2244	(a) the child is harmed because of the child's inhalation or ingestion of cannabis, or
2245	because of cannabis being introduced to the child's body in another manner; or
2246	(b) the child is at an unreasonable risk of harm because of chronic inhalation or
2240	ingestion of cannabis or chronic introduction of cannabis to the child's body in
2248	another manner.
2249	(4) Unless there is harm or an unreasonable risk of harm to the child as described in
2250	Subsection (3), a parent's or guardian's use of medical cannabis or a cannabis product is
2251	not contrary to the best interests of a child if:
2252	(a) for a medical cannabis cardholder after January 1, 2021, the parent's or guardian's
2253	possession or use complies with Title 26B, Chapter 4, Part 2, Cannabinoid Research
2254	and Medical Cannabis, and there is no evidence that the parent's or guardian's use of
2255	medical cannabis unreasonably deviates from the directions of use and dosing
2256	guidelines determined by the parent's or guardian's [qualified medical provider]
2257	recommending medical provider or through a consultation described in Subsection
2258	26B-4-230(5); or
2259	(b) before January 1, 2021, the parent's or guardian's possession or use complies with
2260	Subsection 58-37-3.7(2) or (3).
2261	(5) Subsection (3) does not prohibit a finding of abuse or neglect of a child and Subsection
2262	(3) does not prohibit a finding that a parent's or guardian's use of medical cannabis or a
2263	cannabis product is contrary to the best interests of a child, if there is evidence showing
2264	a nexus between the parent's or guardian's use of cannabis or a cannabis product and
2265	behavior that would separately constitute abuse or neglect of the child.
2266	Section 26. Effective Date.
2267	This hill takes effect on May 7, 2025

2267 <u>This bill takes effect on May 7, 2025.</u>